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Engineering Patterns to Study Vascular Biology
Abstract
Proper growth of blood vessels is critical for development, wound healing and homeostasis. This process
is regulated by a variety of microenvironmental cues including growth factor signaling, cell-cell contacts
and mechanical and biochemical signals from the extracellular matrix. The work presented in this
dissertation encompasses the application of engineering principles to the study of angiogenesis and
vascular biology within the contexts of tissue engineering and vascular disease.
In Chapter 2, we present a novel strategy for generating a spatially patterned vascular network in vivo.
Future development of clinically viable engineered tissues hinges on the ability to generate functional
vasculature capable of delivering blood to parenchymal cells deep within the tissue. The vascularization
strategy described here utilizes tissue constructs that contain patterned ‘cords’ of endothelial cells.
Implantation of these constructs into mice leads to the formation of stable capillaries in a spatially
controlled geometry. The capillaries become perfused with host blood as early as 3 days post
implantation, remain stable for at least 28 days in vivo, are largely comprised of implanted endothelial
cells, and are invested by α-SMA positive pericytes. We further demonstrate that spatial patterning of
vascular architecture improves the function of engineered hepatic tissues. Specifically, co-implantation of
patterned endothelial cell cords with primary hepatocyte aggregates suggested that organized vascular
architecture significantly improved albumin promoter activity within the tissues.
In Chapter 3, we describe the development of an organotypic vascular wall model and show that
pulmonary arterial smooth muscle cells (PASMCs) isolated from patients with idiopathic pulmonary
arterial hypertension (IPAH) exhibit a hyperproliferative phenotype in culture. While normal control
PASMCs display Rac1-mediated growth control, the higher proliferation in IPAH PASMCs is dependent on
increased RhoA activity. We observed that focal adhesion assembly and focal adhesion kinase signaling
are abnormally increased in IPAH PASMCs and show that antagonizing adhesion signaling by direct
inhibition of FAK abrogates IPAH PASMC hyperproliferation in vitro.
In summary, our strategy for rapidly inducing the formation of spatially controlled capillaries comprises a
novel technique for spatial control of vessel growth in vivo. Functional studies with engineered hepatic
tissues also demonstrate the potential of this technique to be used in vascularizing engineered solid
organs. Findings from our investigation into aberrant IPAH SMC proliferation suggest that a
mechanosensitive proliferative control mechanism underlies IPAH etiology.
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ABSTRACT
ENGINEERING PATTERNS TO STUDY VASCULAR BIOLOGY
Jan D. Baranski
Christopher S. Chen

Proper growth of blood vessels is critical for development, wound healing and
homeostasis. This process is regulated by a variety of microenvironmental cues including
growth factor signaling, cell-cell contacts and mechanical and biochemical signals from
the extracellular matrix. The work presented in this dissertation encompasses the
application of engineering principles to the study of angiogenesis and vascular biology
within the contexts of tissue engineering and vascular disease.
In Chapter 2, we present a novel strategy for generating a spatially patterned
vascular network in vivo. Future development of clinically viable engineered tissues
hinges on the ability to generate functional vasculature capable of delivering blood to
parenchymal cells deep within the tissue. The vascularization strategy described here
utilizes tissue constructs that contain patterned ‘cords’ of endothelial cells. Implantation
of these constructs into mice leads to the formation of stable capillaries in a spatially
controlled geometry. The capillaries become perfused with host blood as early as 3 days
post implantation, remain stable for at least 28 days in vivo, are largely comprised of
implanted endothelial cells, and are invested by α-SMA positive pericytes. We further
demonstrate that spatial patterning of vascular architecture improves the function of
engineered hepatic tissues. Specifically, co-implantation of patterned endothelial cell
iii

cords with primary hepatocyte aggregates suggested that organized vascular architecture
significantly improved albumin promoter activity within the tissues.
In Chapter 3, we describe the development of an organotypic vascular wall model
and show that pulmonary arterial smooth muscle cells (PASMCs) isolated from patients
with idiopathic pulmonary arterial hypertension (IPAH) exhibit a hyperproliferative
phenotype in culture. While normal control PASMCs display Rac1-mediated growth
control, the higher proliferation in IPAH PASMCs is dependent on increased RhoA
activity. We observed that focal adhesion assembly and focal adhesion kinase signaling
are abnormally increased in IPAH PASMCs and show that antagonizing adhesion
signaling by direct inhibition of FAK abrogates IPAH PASMC hyperproliferation in
vitro.
In summary, our strategy for rapidly inducing the formation of spatially controlled
capillaries comprises a novel technique for spatial control of vessel growth in vivo.
Functional studies with engineered hepatic tissues also demonstrate the potential of this
technique to be used in vascularizing engineered solid organs. Findings from our
investigation into aberrant IPAH SMC proliferation suggest that a mechanosensitive
proliferative control mechanism underlies IPAH etiology.
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE

1.1 Scope of dissertation
Two studies are presented in this dissertation. In Chapter 2, we describe the development
and application of a novel strategy for vascularizing engineered tissues in vivo. In
Chapter 3, while we begin with a description of work aimed at developing an organotypic
arterial wall model, our main focus shifts to a study into proliferative control mechanisms
that might underlie smooth muscle cells in pulmonary arterial hypertension. A common
introduction to these two studies is presented here in Chapter 1 and is organized as
follows: 1) brief definition and overview of tissue engineering, 2) introduction to
angiogenesis and vascular biology, 3) overview of strategies for promoting angiogenesis
via tissue engineering approaches, and 4) introduction to the pathology of vascular
disease and pulmonary arterial hypertension. Topics including remaining challenges and
future directions are discussed in Chapter 4.

1.2 Introduction to tissue engineering
As medical technology improves and life expectancy throughout the world increases, the
demand for organs grows. Currently, approximately 500,000 patients benefit from organ
transplants in the US each year, and millions of additional surgical procedures are
performed to help replace or reconstruct damaged tissue (Langer & Vacanti, 1993;
Network & Recipients, 2011). The number of organs available for transplant, however,
1

continues to severely outpace demand by an ever-greater margin. Indeed, the median
waiting period for a kidney in the US in 2005 was 1,269 days (Network & Recipients,
2011). Apart from whole organ transplants, therapies utilizing tissue regeneration or
replacement hold much promise for treating a variety of conditions. Considering diabetes
alone, the potential is enormous – 17.5 million patients were affected in the US in 2007,
and the disease represents a $116 billion annual burden in excess medical expenditures
(American Diabetes Association, 2007).
Since first being described in the late 1980s, the field of tissue engineering is
slowly beginning to meet some of the demands for organs and organ replacement
therapies. Its goal is to develop biological substitutes that maintain, improve or restore
normal tissue function (Heineken & Skalak, 1991; Langer & Vacanti, 1993; Vacanti,
2012). Tissue engineering embodies efforts to create new therapies that rely on a
fundamental understanding and control of the structure-function relationship in native
tissues. It is an inherently multidisciplinary field that marries the application of
engineering principles with a fundamental understanding of the underlying biological
processes (Orlando, Wood, et al., 2011b). Though clinical trials with tissue-engineered
therapies have only recently begun, preliminary results from these and other in vitro and
preclinical animal studies strongly suggest that many novel therapies will emerge over
the next several decades.
1.2.1 General strategies in tissue engineering
Tissue engineering originally emerged from the biomaterials field in the 1980s – as the
biophysical properties of natural and synthetic materials were becoming better
2

understood, a growing number of studies utilizing these materials and their interactions
with cells as a means of repairing or replacing injured tissues quickly coalesced into its
own field (Vacanti, 2012). Today, tissue engineering strategies can be divided into two
general categories: 1) ones that rely solely on growth-inducing substances and scaffolds
and 2) ones that rely on cells placed on or within synthetic scaffolds or natural matrices
(Langer & Vacanti, 1993). Accordingly with the field’s origins, a substantial amount of
research has focused on efforts to generate materials with bioactive properties (R. R.
Chen & Mooney, 2003; Lutolf & Hubbell, 2005). Indeed, within the context of vascular
tissue engineering, much work has focused on using biomaterials to help drive the body’s
natural angiogenic processes (Cleary et al., 2012; Lovett, Lee, Edwards, & Kaplan, 2009;
Phelps & García, 2010). Significant contributions in this area include the controlled
release of growth factors for inducing vessel growth (Peters, Polverini, & Mooney, 2002),
insights into of the role of matrix mechanics on capillary morphogenesis (Ghajar, Chen,
Harris, Suresh, et al., 2008a), and the development of a variety of synthetic materials with
broad applications in tissue engineering (Lin & Anseth, 2008; X. Liu, Holzwarth, & Ma,
2012).
To date, tissues with cells of virtually every type have been created in the
laboratory (Orlando, Baptista, et al., 2011a; Orlando, Wood, et al., 2011b). A critical
issue, however, has been a limitation in the number of autologous cells that are available
for use in patients (C. J. Koh & Atala, 2004; Rustad, Sorkin, Levi, Longaker, & Gurtner,
2010). The discovery of inducible pluripotent stem cells in 2006 has provided a potential
solution to the problem of cell source and cell-based therapies are seeing much renewed
3

interest (Rustad et al., 2010). While significant challenges remain, advances in the study
of materials and cell biology are continuing to drive the development of novel and
increasingly effective tissue-engineered therapies.

1.2.2 Current challenges in engineering solid tissues
Therapies for replacing organs such as engineered skin, bladder, airways, urethra and
large blood vessels have recently showed promise in early stage clinical trials and have
already become available to small numbers of patients (Hibino et al., 2011; Macchiarini
et al., 2008; Orlando, Wood, et al., 2011b; H. Yanaga, Imai, Fujimoto, & Yanaga, 2009).
The ability to engineer large solid organs with high metabolic demands such as kidney,
liver and pancreas, however, remains elusive. These cell dense and highly vascularized
tissues are complex and remain difficult to construct in the laboratory (Vacanti, 2012). A
key obstacle to their design is the limitation of diffusion of nutrients and waste products
to and from cells within the tissue. Since cells must be located within 100 - 200 µm of
blood vessels to ensure survival, our ability to create a functional vasculature remains
paramount to overcoming the challenge of creating large organs for use in humans
(Rouwkema, Rivron, & van Blitterswijk, 2008). The development of a strategy to
effectively vascularize engineered tissue is a major goal of the work described in Chapter
2 of this dissertation.
1.2.3 Organotypic models of vascular smooth muscle
An ancillary goal within the field of tissue engineering is to generate physiologically
relevant models of normal and diseased tissues (Garlick, 2007; Inamdar & Borenstein,
4

2011; Paquet et al., 2010). Such models allow a much wider variety of manipulations and
are used for the in vitro study of phenomena that might otherwise be prohibitively
expensive, time consuming, or invasive for in vivo experimentation. In the context of
vascular biology, current organotypic models include microfluidic devices and similar
systems that mimic one or more physiological processes within angiogenesis, vascular
injury, inflammation, and tumor extravasation (Chrobak, Potter, & Tien, 2006; Kamat et
al., 2011; Zervantonakis et al., 2012; Zheng et al., 2012). While the adoption of
endothelial-only angiogenic models has been growing significantly, the development of
more complete arterial wall models has been largely unexplored. Indeed, the few reported
uses of an in vitro EC-SMC bilayer focus on the direct interactions between ECs and
SMCs, and we found no reports of its use to study disease (Fillinger, Sampson,
Cronenwett, Powell, & Wagner, 1997; Niwa, Sakai, Watanabe, Ohyama, & Karino,
2007; Ziegler, Alexander, & Nerem, 1995). In a study presented in Chapter 3 of this
dissertation, we sought to create an organotypic model of vascular smooth muscle for use
in the study of pulmonary arterial hypertension.
Given that smooth muscle cells often differentiate into a synthetic phenotype when
cultured in traditional tissue culture models (Thyberg, Hedin, Sjölund, Palmberg, &
Bottger, 1990), we predicted that an organotypic model such as the one described here
might allow for additional study of IPAH pathobiology in a more physiologically relevant
context.

5

1.3 Angiogenesis in physiology and disease
Angiogenesis, or the sprouting of capillaries from preexisting blood vessels, is a complex
process that relies on a number of spatiotemporally regulated biochemical and
mechanical cues . When tissues within multicellular organisms grow to sizes beyond the
diffusion limit, they rely on angiogenesis to recruit new vessels and gain access to the
blood supply (Carmeliet & Jain, 2000). Furthermore, formation of a functional
vasculature is critical for tissues’ ability to receive nutrients and remove metabolic waste,
and angiogenesis plays a central role in development, wound healing and a number of
disease states with each step regulated by a balance between pro- and anti-angiogenic
cues .
1.3.1 Steps of angiogenesis
Angiogenesis requires the cooperative signaling of a variety of growth factor-mediated
biochemical and matrix-mediated adhesive and mechanical cues. The process begins with
the stimulation of quiescent endothelial cells within existing vessels by proangiogenic
cues (D'Amore & Thompson, 1987). Growth factors such as vascular endothelial growth
factor (VEGF) first stimulate the normally quiescent endothelial cells to begin degrading
the surrounding extracellular matrix (Ferrara, Gerber, & LeCouter, 2003). During these
first steps of angiogenesis, the now active endothelial cells begin secreting matrix
metalloproteinases (especially MMP1, MMP2 and MT1-MMP) to degrade the basal
lamina and the surrounding adventitial matrix (Adams & Alitalo, 2007; Carmeliet, 2003).
Concurrently, the cells begin proliferating and migrating away from the original vessel
and towards the source of guidance cues such as gradients of VEGF or gradients of
6

neural guidance cues such as semaphorins and plexins (Torres-Vázquez et al., 2004). The
intricate sprouting process is further regulated notch and delta-like-4 (Dll4) interactions
in the emerging sprout (Phng & Gerhardt, 2009). While individual endothelial cells first
initiate the sprouting process, the emerging sprout consists of numerous stalk cells
following the guidance of a leader, or tip cell. The sprouting cells actively compete for
the tip cell position in a process that involves the up- and down-regulation of VEGF
receptors and is mediated by Notch and Dll4 signaling (Jakobsson et al., 2010). As
sprouting continues, additional gradients of molecules including platelet-derived growth
factor B (PDGFB) and angiopoietin help recruit supporting pericytes to the nascent
endothelial sprouts (Hellberg, Ostman, & Heldin, 2010; Jain, 2003). At this stage of
angiogenesis, the newly formed vessels begin to form lumens capable of carrying blood
via a process of vacuole fusion (Kamei et al., 2006; Strilic et al., 2009). The maturing
vessels are further stabilized by the presence of blood flow, establishment of tight
junctions via cell-cell interactions between claudins and occludins, and adherens
junctions via VE-cadherin interactions (Dejana & Giampietro, 2012; Dejana, TournierLasserve, & Weinstein, 2009; Jain, 2003). Ultimately, all of these tightly coordinated
steps lead to the development of functional, blood-carrying vessels that may be further
pruned in order to generate an optimal network of vessels capable of effectively
delivering blood to growing or injured tissues (Hlushchuk et al., 2011). Lastly, the
dysregulation of vessel growth contributes to the pathogenesis of many disorders
including pulmonary hypertension (Adams & Alitalo, 2007; Carmeliet, 2003; Carmeliet
& Jain, 2011).
7

1.3.2 Regulation of angiogenesis by growth factors
The process of angiogenesis is regulated by a diversity of cues from growth factors, the
ECM, and cell-cell interactions. Of the soluble factors that regulate angiogenesis, the
VEGF signaling pathway has been the most widely studied. The VEGF gene family
consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PlGF)
(Ferrara et al., 2003). By far, the most studied isoform is VEGF-A, which signals
primarily through VEGFR2 (Adams & Alitalo, 2007). It is essential for embryonic
angiogenesis and deletion of a single allele results in embryonic lethality (Carmeliet et
al., 1996). In general, VEGF-A has been found to be critical for all tissues and
developmental stages in which vessel growth is essential. The VEGF isoforms are
capable of binding to a set of receptor tyrosine kinases, mainly VEGFR-1, VEGFR-2 and
VEGFR-3 (Adams & Alitalo, 2007; Ferrara et al., 2003). VEGFR-2 seems to play a
primary role in modulating the growth and permeability actions of VEGF, and studies
have shown that its knockout in mice leads to a lethal defect in which the vasculature
fails to properly form (Shalaby et al., 1995). In contrast, studies have suggested that
VEGFR-1 may play an inhibitory role by suppressing signaling through VEGFR-2. In
mice, knockout of VEGFR-1 leads to an excess of endothelial cells that assemble into
non-functional disorganized tubules (Fong, Rossant, Gertsenstein, & Breitman, 1995).
While the role of VEGFR-3 is still not entirely clear in angiogenesis, it has been shown to
be important in sprouting and tip cell regulation, lymphatic vessel development, and most
recently, in tumor progression (J.-L. Su et al., 2006; Taipale et al., 1999).
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Platelet-derived growth factor (PDGF) is critical to the later stages of the
angiogenic process (Jain, 2003). Once sprouting is underway, endothelial cells release
PDGF-B to recruit pericytes, which express PDGF receptor-beta (Gaengel, Genové,
Armulik, & Betsholtz, 2009; Hellberg et al., 2010). In vivo studies have shown that
knockout of PDGF-B leads to pericyte deficiencies, which result in fragile and leaky
vessels (Quaegebeur, Segura, & Carmeliet, 2010). PlGF, first thought to be a
proangiogenic factor critical during development, is dispensable during development and
is relevant only in disease(Carmeliet et al., 2001). Similar to VEGF, basic fibroblast
growth factor was one of the first angiogenic factors to be discovered (Carmeliet & Jain,
2011). bFGF and the related family of FGFs bind to FGF receptors (FGFRs) on
endothelial cells or can stimulate angiogenesis indirectly by inducing the release of
angiogenic factors from other cell types (Beenken & Mohammadi, 2009). Most notably,
the inhibition of FGFR signaling in quiescent endothelial cells wash shown to cause
vessel disintegration, suggesting that basal levels of FGF are required for the
maintenance of vascular integrity (Murakami et al., 2008).
Recently, a number of studies have focused on the role of the Ang/Tie signaling system
in angiogenesis (Carmeliet & Jain, 2011). This signaling pathway consists of two
receptors, Tie-1 and Tie-2, and three ligands, Ang-1, And-2 and Ang-4. Overall, the
Ang/Tie receptor/ligand system provides a switch between maintaining vessel quiescence
and allowing existing vessels to respond to angiogenic stimuli. Ang-1 functions as a Tie2
agonist and is released by mural cells, while Ang-2 is a competitive Ang-1 antagonist and
is released by endothelial tip cells (Augustin, Koh, Thurston, & Alitalo, 2009; Gaengel et
9

al., 2009). In quiescent endothelial cell layers such as those present in mature vessels,
Ang-1 helps further stimulate quiescence by causing Tie2 clustering at cell-cell junctions,
recruiting additional mural cells, and stimulating basement membrane deposition
(Saharinen et al., 2008). In an angiogenic context, however, endothelial tip cells release
Ang-2, which antagonizes Ang-1/Tie2 signaling and causes increased angiogenic activity
through enhanced mural cell detachment, increased vascular permeability through
loosening of cell-cell junctions, and eventually increased endothelial cell sprouting
(Augustin et al., 2009).
The most recently implicated signaling system in angiogenesis is the Notch
signaling pathway. During sprouting, activation of VEGFR-2 in tip cells upregulates the
expression of Dll4, a soluble ligand for the Notch receptor (Hellström et al., 2007; Phng
& Gerhardt, 2009). In turn, the Notch activation in neighboring endothelial cells
downregulates VEGFR-2 and upregulates VEGFR-1, making the stalk cells less
responsive to the sprouting activity of VEGF. This interplay between VEGFR-1 and
VEGFR-2 expression in neighboring cells coordinates the cells’ migration toward the tip
cell position within growing sprouts (Gaengel et al., 2009; Jakobsson et al., 2010).
The angiogenic process is tightly regulated by a complex milieu of growth
factors, which are only briefly discussed here. Many additional intricacies in the
regulation of angiogenesis by soluble factors such as Dll4/Notch-mediated competition
between tip and stalk cells, crosstalk between different VEGF isoforms and its receptors,
and the guidance of sprouts via hypoxic and neurovascular guidance cues are also recent
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topics of investigation (Arima et al., 2011; Greenberg et al., 2008; Jakobsson et al.,
2010).
1.3.3 Regulation of angiogenesis by the extracellular matrix
The ECM provides cells with a physical anchorage to their surrounding environment and
is often a dynamic component of the cellular microenvironment. Vascular cells adhere to
the surrounding ECM through integrins and actively degrade and secrete new matrix
during periods of angiogenic activity (Carmeliet, 2003; D'Amore & Thompson, 1987).
Due to the heterodimeric nature of integrins and their ability to signal bidirectionally,
integrin signaling during angiogenesis is both more complex and less well understood
than growth factor signaling. While not all integrins are expressed in quiescent
endothelium, integrins α1β1, α2β1, α4β1, α5β1, α6β1, α9β1, α6β4, αvβ3 and αvβ5 have
all been implicated in angiogenesis (Avraamides, Garmy-Susini, & Varner, 2008;
Desgrosellier & Cheresh, 2010; Hodivala-Dilke, 2008). Animal and in vitro studies and
have shown that blocking integrin αvβ3, αvβ5, α5β1, α1β1, or α2β1 inhibits angiogenesis
in vivo or in ex vivo angiogenic models (Brooks, Silletti, Schalscha, Friedlander, &
Cheresh, 1998; Friedlander et al., 1995; Kim, Bell, Mousa, & Varner, 2000; Senger et al.,
1997). Integrins αvβ3 and αvβ5 are particularly well studied and appear to be upregulated
in response to proangiogenic factors in both healthy tissues and in tumors (Avraamides et
al., 2008; R. Silva, D'Amico, Hodivala-Dilke, & Reynolds, 2008). Further complexity,
however, is suggested by integrin knockout studies, which suggest that integrins αv, β3,
β5 and α2 are not always required for angiogenesis (Bader, Rayburn, Crowley, & Hynes,
1998; X. Huang, Griffiths, Wu, Farese, & Sheppard, 2000; Zhang et al., 2008).
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Given integrins’ ability to transmit signals bidirectionally across the cell
membrane and to interact with a variety of extracellular molecules, they are said to
function as hubs that coordinate endothelial cell behavior during angiogenesis (Contois,
Akalu, & Brooks, 2009). Specifically, integrins possess the ability to bind to growth
factors such as VEGF, bFGF, and Ang-1 as well as receptors including VEGFR-2 and
FGFR (Avraamides et al., 2008). These interactions have been shown to stimulate vessel
growth by upregulating and activating proteases secreted by invading tip cells and
promoting vessel maturation by enhancing the adhesion of endothelial cells and pericytes
to their shared basement membrane (Desgrosellier & Cheresh, 2010; Hodivala-Dilke,
2008).
Finally, it is important to note the role of the ECM components in regulating
angiogenesis. Endothelial cells and the surrounding pericytes share a basement
membrane that is primarily composed of laminin and type IV collagen (Carmeliet, 2003;
Simon-Assmann, Orend, Mammadova-Bach, Spenlé, & Lefebvre, 2011). During
sprouting, the basement membrane and surrounding ECM components must be degraded
in order to allow for the migration of emerging sprouts. Upon induction of angiogenic
sprouting, proteases such as MT1-MMP proteolytically degrade the basement membrane
and expose cryptic chemotactic motifs in the ECM (Carmeliet, 2003; Chun et al., 2004).
The degradation of the surrounding matrix allows for the deposition of provisional matrix
proteins such as fibronectin and denatured collagen, which again signal through integrins
(Arroyo & Iruela-Arispe, 2010). In addition, the newly exposed cryptic binding sites
provide additional proangiogenic signaling cues that were not present in the quiescent
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state (Ghajar, George, & Putnam, 2008b). A specific example includes the cleavage of
type IV collagen, which exposes cryptic binding sites that bind upregulated αvβ3
integrins during angiogenesis (J. Xu et al., 2001). During quiescence, the presence of the
surrounding ECM components helps maintain endothelial cells in an antiproliferative
state (Carmeliet & Jain, 2011). Lastly, MMPs help regulate the angiogenic process by
liberating matrix-bound growth factors such as VEGF and FGF (Bergers et al., 2000).
While matrix bound isoforms of VEGF have been shown so support vessel branching,
soluble VEGF that has been cleaved by MMPs has been shown to enlarge vessels (IruelaArispe & Davis, 2009). An additional layer of complexity is introduced into the
regulation of angiogenesis by proteases due to their ability to release anti-angiogenic
signals such as angiostatin (Folkman, 2007).
1.3.4 Regulation of angiogenesis by cell-cell contacts
Due to the multicellular nature of blood vessels, cell-cell junctions play a fundamental
role in all steps of angiogenesis (Nguyen & D'Amore, 2001). Notably, a major form of
endothelial cell-cell signaling occurs through gap junctions via the connexin family of
proteins (Söhl & Willecke, 2004). These proteins have traditionally been studied most
thoroughly in quiescent vessels, where endothelial cells use this signaling mechanism for
long distance communication. In this context, studies have shown that signaling via gap
junctions regulates growth and differentiation of cells within the vessels (Gärtner et al.,
2012). The role of connexins in angiogenesis, however, is less well understood. 21
different connexins have been identified in humans and they exhibit tissue-specific
expression patterns (Söhl & Willecke, 2004). Additional complexity is introduced by the
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involvement of different connexins in endothelial-endothelial, smooth muscle-smooth
muscle and endothelial-smooth muscle gap junctions. Nevertheless, studies have shown
that endothelial specific knockout of Cx40 and Cx37 in mice results in severe vascular
abnormalities (Simon & McWhorter, 2002). In conjunction with cell culture models,
these studies have suggested the importance connexins in the angiogenic process
(Bazzoni & Dejana, 2004; Hill, Rummery, Hickey, & Sandow, 2002). The underlying
mechanisms, however, remain an area of ongoing research.
In addition to gap junctions, quiescent endothelial cells normally maintain cellcell junctions via tight junctions (claudins, occludins) and adherens junctions (cadherins)
(Jain, 2003). During angiogenesis, however, the junctions between endothelial cells are
temporarily dissociated, thus limiting the role of cell-cell junctional proteins in sprouting
endothelial cells to steps in which the cells are acting as a synchronized unit (Wallez &
Huber, 2008). Within this context, studies have shown that VE-cadherin is required for
proper lumen formation and localization of CD34 (Strilic et al., 2009). During the latter
stages of angiogenesis, N-cadherin stabilizes contacts between endothelial cells and
pericytes, which in turn enhance the production of basement membrane proteins
including laminins and collagen IV (Stratman, Malotte, Mahan, Davis, & Davis, 2009).
Ultimately, it is a complex interplay of pro- and antiangiogenic growth factors,
extracellular signals from the ECM, and cell-cell signals that drive the coordinated
process of vessel formation. Given the complexity of this system, it ensures that an
optimal vascular network is formed during development and wound healing. It is this
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complexity, however, that also makes angiogenic pathways susceptible to a variety of
misregulated signals during disease (Ferrara & Kerbel, 2005).
1.3.5 Therapeutic angiogenesis and its role in the clinic
Blood vessels nourish virtually every organ in the body and are critical for development,
wound healing and maintenance of homeostasis. In disease, however, insufficient vessel
growth can lead to stroke, myocardial infarction, ulcerative disorders and
neurodegeneration (Carmeliet & Jain, 2000). Abnormal vessel growth helps drive cancer,
inflammatory disorders and pulmonary hypertension among other diseases (Carmeliet,
2003; Folkman, 2007). While anti-angiogenic therapies are by far more widely studied,
therapeutic vascularization of ischemic tissues remains a central goal in the study of
angiogenesis. Treatment of ischemic heart disease via angiogenic therapies, for example,
is receiving significant interest after several clinical studies have demonstrated
preliminary success in providing additional blood flow to poorly vascularized areas in
patients with myocardial ischemia (Laham et al., 1999; Rosengart et al., 1999;
Schumacher, Pecher, Specht, & Stegmann, 1998). In such physiologic contexts where
revascularization of injured tissues is delayed or pathological due to insufficient vessel
growth, VEGF-related therapies remain the most widely studied (Carmeliet, 2003). Other
angiogenic therapies, however, that attempt to introduce angiogenic cues from sources
such as platelets and monocytes are also being considered (Bottomley et al., 1999; Griga,
Werner, Köller, Tromm, & May, 1999).
Given the inherent complexities that underlie the formation of a stable and
functional vasculature, effective angiogenic therapy remains a difficult goal. Indeed,
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attempts at promoting new vessel growth that hinge upon the delivery of single growth
factors such as VEGF or bFGF have led to the formation of leaky vessels and failed in
clinical trials (Henry et al., 2001; Stewart et al., 2009). As additional angiogenic
pathways are being elucidated, new clinical targets are continually emerging. For
example, angiopoietin has now been shown to help repair or prevent damaged and leaky
vessels in diabetic retinopathy, acute macular degeneration, and ischemia/reperfusion
injury (Thurston et al., 2000; 1999). Overall, molecules from the VEGF family,
Angiopoietin-1, β-Estradiol, the FGF family, IL-8, Leptin, MCP-1, MMPs, NOS, PDGFBB, TNF-α, Angiogenin, TGF have all been studied in various animal models with
promising preclinical results (Pandya, Dhalla, & Santani, 2006).
A variety of novel approaches to deliver proangiogenic agents have also recently
been developed. These range from gene therapy approaches utilizing viral delivery of
recombinant growth factors to biomaterials with controlled release properties (Ferrara &
Kerbel, 2005; Folkman, 2007; Pandya et al., 2006). Despite advances, the clinical
viability of these therapies remains to be tested in a controlled setting. Notably, initial
trials in which patients with myocardial or limb ischemia were treated with VEGF-A,
VEGF-C, FGF-1, FGF-2 and FGF-4 showed promising results, but larger placebocontrolled trials that utilized recombinant proteins or gene therapy later yielded only
marginal results (Henry et al., 2003; Lederman et al., 2002; Simons, 2005). Most
recently, attempts at cell-based strategies for revascularization using bone-marrow
derived endothelial progenitor cells have demonstrated additional promise (Rafii &
Lyden, 2003). Transplantation of bone marrow mononuclear cells into ischemic muscle
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of patients suffering form peripheral arterial disease resulted in restored limb function
(Tateishi-Yuyama et al., 2002; Tomita et al., 1999). Larger placebo-controlled studies,
however, will again be required to validate these findings and assess long-term benefits.
The failures of growth factor therapies and emergence of cell-based strategies
highlights the need for a more integrated approach to angiogenic therapies (Yoshida et
al., 2010). In an attempt to help restore the appropriate microenvironmental cues
necessary for proper vascularization of tissue, many tissue-engineered vascularization
strategies are quickly emerging as potentially viable methods for properly revascularizing
injured tissues (Thwaites, Reebye, Mintz, Levicar, & Habib, 2012).

1.4 Tissue engineering approaches to promote angiogenesis
Shortly after the inception of tissue engineering as a field, vascularization quickly
emerged as a central topic of research (Kaully, Kaufman-Francis, Lesman, & Levenberg,
2009; Lovett et al., 2009). The need to vascularize engineered tissues combined with
unmet clinical needs for therapeutic angiogenesis have sparked significant research
efforts. Novel integrated approaches that utilize growth factors, synthetic matrices and
cells often in combination hold great promise. It should be noted, however, that this area
of research is in a much more nascent state than the angiogenic therapies discussed in the
previous section, and none of the approaches discussed here have yet been thoroughly
tested in human clinical trials. As these efforts begin to enter human trials over the
coming years, a number of viable approaches are likely to emerge (Orlando, Wood, et al.,
2011b). The current strategies for vascularization and promoting angiogenesis can be
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categorized into two major categories: 1) approaches that utilize biofunctional materials
and 2) approaches that utilize cells to induce vascularization (Lovett et al., 2009).
1.4.1 Biofunctional materials for inducing angiogenesis
Given our understanding of the role of cell-matrix and cell-cell adhesive and mechanical
cues in the angiogenic process, it is clear that proper signals from the ECM are necessary
for effective vessel growth. A variety of both natural and synthetic materials have been
studied for their ability to provide these cues (Lutolf & Hubbell, 2005; Moon et al., 2011;
Tian & George, 2011). Two synthetic material backbones have been primarily used for
inducing vascularization: poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol
(PEG) hydrogels. PLGA, a biodegradable and biocompatible polymer, has been used
extensively in medicine as a temporary mechanical support in implantable medical
devices (Athanasiou, Niederauer, & Agrawal, 1996). The use of synthetic polymers for
inducing angiogenesis allows full control over a number of material properties and avoids
the risks associated with using potentially immunogenic natural materials (Lutolf &
Hubbell, 2005; Orlando, Wood, et al., 2011b). Most notably, Mooney and colleagues
have developed implantable PLGA scaffolds that sequentially release VEGF and PDGF
and induce vessel ingrowth when implanted into mice (R. R. Chen, Silva, Yuen, &
Mooney, 2006). While promising, it is not yet clear whether this approach is capable of
generating mature vessels that remain stable over long periods of time (Peters et al.,
2002). Most recently, studies utilizing this approach have also demonstrated that
combinations of bFGF, VEGF and S1P are also capable of inducing vascularization in
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vivo (Tengood, Kovach, Vescovi, Russell, & Little, 2010; Tengood, Ridenour, Brodsky,
Russell, & Little, 2011).
Recently, PEG hydrogels have emerged as an alternative synthetic scaffold for
inducing angiogenesis (Zisch et al., 2003). Since natural ECMs are hydrogels, the
structure of PEG provides a close synthetic mimic for host ECM (Moon et al., 2011).
PEG hydrogels also possess highly tunable mechanical properties and can be
functionalized with various proteins or peptides to render the material adhesive and
degradable (Lutolf & Hubbell, 2003). Angiogenic studies with PEG hydrogels have
demonstrated enhanced angiogenesis using the materials in in vitro, ex vivo and in vivo
models of angiogenesis (Leslie-Barbick, Moon, & West, 2009; Moon, Lee, & West,
2007).
While promising, the application of synthetic or natural matrices alone has yet to
demonstrate the ability to rapidly vascularize tissues. These approaches, however, are
helping to provide insights into the design of more complicated strategies involving the
use of exogenous cells. For example, Putnam and colleagues have focused on the
interplay between ECM mechanics and vascularization potential (Ghajar, Chen, Harris,
Suresh, et al., 2008a; Kniazeva & Putnam, 2009). This work is paving the road for
understanding critical design parameters in developing the next generation of
vascularization strategies.
1.4.2 Cell-based strategies for generating microvasculature
A critical drawback of vascularization strategies that rely on the use of acellular synthetic
or natural matrices is the inability to rapidly vascularize an engineered or damaged host
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tissue (X. Chen et al., 2010; Jain, Au, Tam, Duda, & Fukumura, 2005). Specifically, large
engineered tissues must become quickly vascularized (1-2 days) upon implantation in
order to prevent parenchymal cell death (Orlando, Baptista, et al., 2011a). In a disease
setting, ischemic tissues need to be revascularized as quickly as possible to minimize
necrosis and tissue damage. Accordingly, attempts to more rapidly vascularize tissues
have attempted to leverage the use of cells embedded within natural or synthetic scaffolds
to help speed up the vascularization process (Kaully et al., 2009; Lovett et al., 2009).
The driving principle behind cell-based vascularization strategies is to implant a
rudimentary vascular network or a population of vascular cells capable of rapidly
connecting with the host vasculature (X. Chen et al., 2009). Most current studies in this
area remain limited to natural matrices. Though synthetic polymer chemistry is advancing
rapidly, natural matrices inherently posses the proper adhesive, mechanical and
degradable properties known to be necessary for proper vascularization (Kaully et al.,
2009). It is likely that a switch to synthetic materials will occur over time as they become
better understood and more tunable to these applications.
A seminal study in the area of cell-based vascularization approaches was first
performed by Jain and colleagues in which they combined endothelial cells and
embryonic mesenchymal cells in a type I collagen gel (Koike et al., 2004). Implantation
of this construct into mice resulted in the formation of vessels that remained stable for
four months. Furthermore, portions of the vessel walls contained the originally implanted
cells, demonstrating for the first time that exogenous cells directly contribute to the
formation of vessels. Subsequent studies have since focused on varying cell-type, ECM
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material or in vitro culture conditions in an attempt to find a set of optimal conditions for
generating functional vasculature in vivo (Lovett et al., 2009). In another study Jain and
colleagues used endothelial progenitor cells to demonstrate the ability of their engineered
vessels to remain stable up to one year in vivo upon implantation (Au, Tam, Fukumura, &
Jain, 2008b). Most recently, work by George and colleagues has focused on rapidly
vascularizing the engineered tissues once implanted. Using endothelial cells and a variety
of supporting cell types embedded in a fibrin matrix, they demonstrated the formation of
perfused vessels within one day of implantation (X. Chen et al., 2009; 2010). Additional
biological insights have shown that the type of cell used within these engineered
constructs can come from an autologous source (Melero-Martin et al., 2008), and that the
presence of myeloid cells, an immune component, is necessary for proper vessel
formation (Fantin et al., 2010). Evidence also suggests that implanted vascular cell
networks anastomose with the host vasculature via a novel “wrapping-and-tapping”
mechanism (Cheng et al., 2011).
While work is underway to gain a better understanding of the vascularization
mechanisms within these engineered constructs – likely a combination of vascular
network assembly, angiogenesis and anastomosis – basic insights have already begun to
drive their application towards generating functional engineered tissues (Orlando,
Baptista, et al., 2011a; Vacanti, 2012). One particular area of focus is that of vessel
organization. To date, all cell-based vascularization techniques have used randomly
seeded cells within a scaffold that provide no specific patterning cues to the growing
vasculature (Zheng et al., 2011). Interestingly, George and colleagues have demonstrated
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that by preculturing cells within fibrin constructs, which allows them to organize into
rudimentary networks, a more rapid formation of perfused vasculature can be achieved in
vivo upon implantation (X. Chen et al., 2009). More recent work has shown that
organized vessel networks improve the function of skeletal muscle grafts upon
implantation (Koffler et al., 2011). Together these studies suggest that patterning of
engineered vasculature is an area worthy of further investigation. Indeed, vasculature
generated via developmental processes is guided by a number of patterning cues and,
through a sequence of regulated spatiotemporal signals, reaches a geometry that is
optimal for the perfusion of the surrounding tissue (LaRue et al., 2003; Melani &
Weinstein, 2010; Rivron et al., 2012; Ruhrberg et al., 2002). In the engineered context, an
ability to pattern the vasculature de novo would usher in the possibility of studying
optimal vessel patterns and subsequently using them to develop larger functional
engineered tissues for use in the clinic (Orlando, Baptista, et al., 2011a; Rustad et al.,
2010).

1.5 The vasculature in a disease context: pulmonary arterial
hypertension
Proper vessel function is critical for maintaining homeostasis in healthy organisms.
Malformations or aberrant vessel function contribute to the pathogenesis of many
diseases, and cardiovascular disease remains the biggest cause of deaths worldwide
(Carmeliet, 2003; Carmeliet & Jain, 2000; Lloyd-Jones et al., 2010). One specific
example includes pulmonary arterial hypertension (PAH), a condition characterized by
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elevated pulmonary arterial pressure (Lourenço, Fontoura, Henriques-Coelho, & LeiteMoreira, 2011). In patients with PAH, the increased vascular resistance in the pulmonary
circulation places a greater workload on the heart and ultimately leads to right ventricular
failure and premature death. PAH can be hereditary, associated with other conditions
(including congenital heart disease, HIV and others) or idiopathic. Idiopathic pulmonary
arterial hypertension (IPAH), which occurs in the absence of identifiable risks, is
particularly difficult to diagnose (Gaine & Rubin, 1998; Rubin, 1997). Patients present
with general symptoms and diagnosis is only made after the exclusion of other heart and
lung diseases known to cause elevations in pulmonary arterial pressure (Chin & Rubin,
2008). In patients with IPAH, the estimated survival rates for patients receiving treatment
at 1, 2, and 3 years are 83, 67, and 58%, respectively (Humbert et al., 2010). Despite
advances in hypertension research, no cure currently exists for PAH (Agarwal &
Gomberg-Maitland, 2011).
1.5.1 Pathology and current treatments
Pulmonary arterial hypertension is typified by hyperproliferation and remodeling within
the small pulmonary arteries, which results in increased blood pressure within the lung
vasculature. Characteristic abnormalities in the pulmonary arteries of PAH patients
include thickening of the intimal, medial and adventitial compartments (Chin & Rubin,
2008; Gaine & Rubin, 1998; Rubin, 1997). Detailed histological examination of
pulmonary arterioles in patients with IPAH shows neointimal thickening, pulmonary
arteriolar occlusion, and plexiform lesions, suggesting that IPAH is a primarily
vasoproliferative disease with accompanying vasoconstriction as well as catabolism and
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de novo synthesis of components of the extracellular matrix (ECM) (Chin & Rubin, 2008;
Farber & Loscalzo, 2004; Humbert et al., 2004; Jones & Rabinovitch, 1996; Jones,
Cowan, & Rabinovitch, 1997; Pietra et al., 1989).
Three classes of drugs are currently used to treat PAH: prostacyclin analogs,
endothelin receptor antagonists and phosphodiesterase type 5 inhibitors (Agarwal &
Gomberg-Maitland, 2011). The vasoconstriction and progressive vascular cell
proliferation seen in PAH patients may stem from low levels of endogenous prostacyclin
(Rubin et al., 1982). Thus, prostacyclin analogs were introduced to target the
prostaglandin I receptor, which is capable of inducing potent vasodilation through the
activation of cyclic adenosine monophosphate (Agarwal & Gomberg-Maitland, 2011).
The most notable drug in this category and the current first-line preferred drug for PAH
treatment is epoprostenol. Its long-term benefits have been reported by two large centers
and it remains as the only therapy for advanced PAH that has proven to enhance survival
(Barst et al., 1996). While demonstrating very favorable outcomes and improving
patients’ quality of life significantly, its administration remains complicated due to the
compounds’ 3-5 min plasma half-life (Fuentes, Coralic, & Dawson, 2012). Because of
this limitation, patients undergoing treatment with epoprostenol must use a continuous
infusion IV pump, which requires daily care and maintenance (Agarwal & GombergMaitland, 2011). More recently, two newer prostacyclin analogs have been introduced
with longer half-lives, which allow for subcutaneous or inhalable routes of administration
(Laliberte, Arneson, Jeffs, Hunt, & Wade, 2004; McLaughlin et al., 2010).

24

Endothelin-A and endothelin-B are targets of the second class of drugs used in the
treatment of PAH . Endothelin-1 is a potent vasoconstrictor and has been shown to
increase smooth muscle cell proliferation (Boniface & Reynaud-Gaubert, 2011).
Endothelin-1 levels in the circulating plasma of PAH patients are increased, further
suggesting that its receptors may be a good target for treating PAH (Rubens et al., 2001).
Bosentan and ambrisentan are two endothelin receptor antagonists currently in use today.
While administration of these two drugs must be closely monitored due to potential liver
toxicity issues, they remain widely prescribed to PAH patients (Rubin et al., 2002; Vatter
et al., 2002).
Phosphodiesterase inhibitors act by inhibiting phosphodiesterase 5 in the nitric
oxide-cGMP pathway. Briefly, nitric oxide elicits vasodilatory and antiproliferative
effects via the release of cyclic guanosine monophosphate (cGMP). cGMP, however, is
typically rapidly broken down by phosphodiesterase 5 (Agarwal & Gomberg-Maitland,
2011). Thus, this category of PAH drugs aims to induce pulmonary vasorelaxation by
preventing this rapid degradation of cGMP (Agarwal & Gomberg-Maitland, 2011).
Sildenafil and tadafil comprise this category of drugs and are both administered orally
(Galie et al., 2009; Ghofrani et al., 2002).
Despite the continuous development of drugs in each category, none of these
effectively treat the underlying pathophysiology of PAH. Exercise capacity and, more
importantly, pulmonary arterial pressures are never returned to normal levels upon
administration of these compounds. Over time, even despite the introduction of
combination therapies, quality of life in patients remains relatively low and no further
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treatments outside the realm of lung transplantation currently exist (Agarwal &
Gomberg-Maitland, 2011; Lourenço et al., 2011). Lastly, it should be noted that most of
the currently administered drugs have been approved based on short-term studies. Few
long-term well-controlled studies have been done to assess clinical outcomes (Barst et al.,
2009). In summary, while significant advances in the treatment of PAH have been made
over the past two decades, no cure currently exists and little is understood about the
underlying etiology of the disease.
1.5.2 The role of vascular smooth muscle cells in pulmonary hypertension
The majority of drugs first used in treating PAH were chosen for their vasodilatory
effects. However, several have now demonstrated anti-proliferative effects in vitro and in
animal models (Jiang, Zhou, & Liu, 2012; Wolf, Sauter, Risler, & Brehm, 2005).
Abnormal SMC proliferation within pulmonary arteries of PAH patients is one of the
hallmark characteristics of the disease (Humbert et al., 2004; Lourenço et al., 2011).
Hyperproliferating SMCs are found in the plexiform lesions that are found occluding the
intraluminal space in patients with sever PAH (Pietra et al., 1989).
It was shown more than thirty years ago that injured SMCs undergo a shift from a
contractile phenotype to one that is synthetic and characterized by increases in
proliferation, migration and ECM synthesis (Chamley, Campbell, McConnell, &
Gröschel-Stewart, 1977). Subsequently, work over the past several decades has begun to
focus on identifying drugs that are effective at inhibiting this proliferative response in
PAH. Several studies demonstrated the ability of statins to inhibit SMC proliferation and
migration and slow intimal hyperplasia (Corpataux, Naik, Porter, & London, 2005;
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Corsini et al., 1999; Porter et al., 2002)). It has been reported that a possible mechanism
of action in this context is through Rho GTPase prenylation (Laufs, Marra, Node, & Liao,
1999). More recent studies have specifically implicated aberrant PDGF signaling in SMC
hyperproliferation (Humbert et al., 2004). Ito and colleagues showed that PDGF
stimulation of SMCs isolated from lungs of PAH patients resulted in higher proliferation
rates than those in control SMCs (Ogawa et al., 2005). In a follow-up study, they further
demonstrated that simvastatin inhibits this PDGF-induced hyperproliferation through an
upregulation of the cell cycle inhibitor p27 (Ikeda et al., 2010). Interestingly, they found
that simvastatin treatment correlated with the disorganization of actin fibers and the
inhibition of Rho translocation from the cytoplasm to the membrane, again suggesting
that Rho GTPase signaling may play an important role. Their basic findings are also
supported by studies that demonstrate the reversal of experimentally induced PAH in
rodent models via the administration of PDGF inhibitors (Schermuly et al., 2005).
In addition to PDGF, studies have also begun to implicate serotonin in PAH SMC
hyperplasia (Lourenço et al., 2011). Eddahibi and colleagues have found that increased
serotonin activity through upregulation of the 5-HTT serotonin transporter in isolated
PAH SMCs or animal models of PAH contribute to SMC hyperproliferation (Guignabert
et al., 2006; Marcos et al., 2004). Inhibition of 5-HTT in a rodent PAH model also
suggested that it is a novel target worthy of consideration in the search for additional
therapies. Finally, two studies have implicated aberrant endothelial-SMC interactions
(Eddahibi et al., 2006) and glycogen synthase kinase 3beta (Sklepkiewicz et al., 2011) as
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having direct involvement in the progression of PAH. Combined, these studies give hints
at the types of molecular targets that might be at the focus of future PAH therapies.
1.5.3 Regulation of smooth muscle cell proliferation by the microenvironment
Fully differentiated smooth muscle cells in the healthy adult typically exhibit very low
rates of proliferation (S. Schwartz, Campbell, & Campbell, 1986). During times of injury
or vascular disease, however, these cells undergo a phenotypic switch and begin
proliferating rapidly (A. W. Clowes, Reidy, & Clowes, 1983). While SMC proliferation
is largely controlled by the same mechanisms as in other cell types, there are several
microenvironmental cues that are of additional relevance when considering smooth
muscle cell biology in the disease context. First, growth factors and other compounds that
are involved in angiogenesis and vascular disease such as nitric oxide, EGF and PDGF
have been shown to regulate SMC proliferation in vivo (Ferns et al., 1991; Lindner &
Reidy, 1991; Nabel et al., 1993).
PDGF is a potent activator of SMC proliferation that is thought to primarily
upregulate SMC proliferation via activation of ERK (Zhan et al., 2003). As discussed in
the previous section, PDGF-induced hyperproliferation in PAH is now being directly
targeted by several drugs. The effects of inhibiting downstream effectors such as ERK in
PAH models, however, remain to be investigated. Although the antiproliferative effects
of nitric oxide, a widely used and studied vasodilator, have been known for some time, its
mechanisms of action are very broad and are still being studied today (Tsihlis et al.,
2011). In general, however, it is known that NO relies on the upregulation of cGMP and
subsequent downregulation of the EGF-MAP kinase cascade (Yu, Hung, & Lin, 1997).
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Overall, essentially all potent SMC mitogens tend to activate receptors with intrinsic
tyrosine kinase activity (Cadena & Gill, 1992). In turn, these receptors activate
corresponding intracellular pathways including MAP kinase, protein kinase B and protein
kinase C (Berra et al., 1993; Coffer, Jin, & Woodgett, 1998; Seger & Krebs, 1995).
Ultimately, these growth factors share activation of the cyclin-dependent kinases in the
cell cycle pathway as a final common signaling pathway (Newby & Zaltsman, 2000).
In addition to growth factors, vascular SMC proliferation is regulated by other
extracellular cues derived from the surrounding ECM(Assoian & Marcantonio, 1997).
Most notably, heparan sulfate proteoglycans inhibit proliferation directly by inhibiting
signaling by growth factors via the protein kinase C pathway (Y. Wang & Kovanen,
1999). Other components of the basement membrane have also been shown to help
maintain a non-proliferative phenotype in normal SMCs. Specifically, Ross and
colleagues showed that fibrillar collagen (versus monomeric) inhibits SMC proliferation
via Cdk2 (Koyama, Raines, Bornfeldt, Roberts, & Ross, 1996). Lastly, mechanical
stimuli such as stretch and ECM stiffness have begun to emerge as additional effectors of
SMC proliferation (Gambillara, Thacher, Silacci, & Stergiopulos, 2008; C. Li & Xu,
2000; Shaw & Xu, 2003; Shyu, Chao, Wang, & Kuan, 2005). While regulation of
proliferation via mechanical stimuli has been shown in other cell types, we now know
that stretching of the ECM substratum can induce SMC proliferation in the absence of
cell-cell contacts (W. F. Liu, Nelson, Tan, & Chen, 2007). Overall, recent insights into
the pathophysiology of PAH suggest that regulation of SMC proliferation via ECM
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signals and mechanics may play a role in the disease progression. This area of research,
however, remains largely unexplored in the context of PAH.

1.6 Summary
Over the last several decades, our knowledge of vascular disease and the underlying
biology have increased tremendously. Studies described in the preceding sections have
served as the inspiration for the work presented in the subsequent chapters. First, a study
on the topic of engineered vasculature is presented in Chapter 2. This research draws on
existing insights into the fundamental processes that underlie angiogenesis and attempts
to extend current microvascular engineering approaches by introducing the ability to
geometrically pattern vessels in vivo. Second, our study of PAH presented in Chapter 3
provides new insights into the proliferative regulation of IPAH SMCs. In a broader
context, these two studies comprise part of an ongoing paradigm shift in the fields of
bioengineering. Drawing upon decades of ongoing research into fundamental biological
processes, tissue engineering strategies and therapeutic approaches for treating vascular
disease are increasingly being designed based less on anecdotal findings and more on a
fundamental understanding of the underlying biological processes.
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CHAPTER 2: Patterned vascular networks improve function of
engineered tissues in vivo

2.1 Introduction
Engineered organ tissues are emerging as a new class of therapies to combat the scarce
supply of heterologous donor organs available for transplant (Vacanti & Langer, 1999).
While highly promising, a critical limitation in the field is the successful vascularization
of large tissue constructs (Orlando, Baptista, et al., 2011a; Rustad et al., 2010). The future
utility of engineered tissues relies on the development of vascular architectures that
effectively deliver blood to these large and geometrically complex tissues (Kaully et al.,
2009).
In vivo, native tissue is comprised of specialized cells and vasculature embedded
within tissue specific ECM in a highly organized manner. The liver, in particular, has a
precisely-defined microarchitecture involving a complex interplay between hepatocyte
cords, bile canaliculi, and microvessel networks that is thought to impact metabolic mass
transport and tissue function (Reid, Fiorino, Sigal, Brill, & Holst, 1992). Indeed, it is the
loss of this architecture due to replacement by fibrotic tissue and regenerative nodules
that defines chronic cirrhosis (Ishibashi, Nakamura, Komori, Migita, & Shimoda, 2009).
Successful therapeutic tissue engineering strategies will rely in part on the ability to
recapitulate proper tissue organization by integrating defined vascular networks with
tissue specific cellular structures. However, current strategies to study the combined
effects of vascular organization and parenchymal juxtaposition have been limited to
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random vascular self-assembly and tubulogenesis within natural and engineered ECMs as
described above in section 1.3.2. While promising, such strategies are currently unable to
provide the spatial and geometric control of vessel architecture that is necessary for
parenchymal cell survival within solid tissues (Vacanti, 2012).
In this chapter, we describe the development and application of a novel approach
for creating functional, spatially organized vascular architectures within engineered
tissues. The underlying hypothesis of our work is that patterned constructs of endothelial
cells can be used to induce vascularization in vivo. Our approach utilizes micropatterning
techniques to organize endothelial cells into geometrically defined ‘cords’ that drive the
formation of fully functional, patterned capillaries upon implantation into mice. We also
demonstrate the ability of our vascularization strategy to maintain the viability and proper
function of engineered hepatic tissue.

2.2 Generation of patterned endothelial cell ‘cords’ in vitro
2.2.1 Design, fabrication and optimization of a second-generation device for
generating patterned cell cords
Previous efforts in our laboratory have focused on the development of a technique for
spatially patterning cells within micromolded collagen gels (Fig. 2.1A) (Raghavan,
Nelson, Baranski, Lim, & Chen, 2010a). Using this technique, it was demonstrated that
patterning endothelial cells embedded within collagen could be used to generate ‘cords’
that contain cell-cell junctions characteristic of physiologic endothelium (Fig 2.1B).
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To enable their implantation and use in animal studies, we demonstrated that these cords
could be removed from their underlying polydimethylsiloxane (PDMS) templates (Fig.
2.2). This removal was accomplished by embedding the fully formed cords within a
collagen gel, allowing the entire collagen/cord construct to be mechanically separated
from the PDMS device. Use of PBS during the removal process helped to reduce damage
to the construct and aid in its removal .
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Figure 2.1 Early technique for generating patterned cell cords (A) Schematic of
method for generating cords by organizing cells and collagen within
microfabricated PDMS channels. (B) Phase contrast images of cords formed
within 50 µm wide and 50 µm tall channels after 24 h in culture. (C) Fluorescence
images of endothelial cell cords (red and green, actin; blue, nuclei) consisting of
HUVECs and BAMECs cultured for 48 and 24 h, respectively. (D) PECAM
(CD31) and β-catenin (E) are found at cell-cell junctions in EC cords. BAMECs,
bovine adrenal microvascular endothelial cells. Data reprinted with permission
(Raghavan, Shen, Desai, Sniadecki, Nelson, & Chen, 2010b).
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Figure 2.2. Removal of cords from PDMS template. Phase contrast (A) and
fluorescence (B) images of HUVEC cords removed after 24 h in culture into 2.4
mg/ml collagen gel. Cells are labeled for actin (green) and nuclei (blue). Data
reprinted with permission (Raghavan, Nelson, Baranski, Lim, & Chen, 2010a).

Given the ability to remove cords from the PDMS templates, we hypothesized
that they could be used to generate geometrically defined vascular networks in vivo.
Others have previously shown that improved organization of endothelial cell networks
and transplanted capillary beds leads to improved vascularization (X. Chen et al., 2009;
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Laschke et al., 2010). We predicted that the established cell-cell contacts within cords
comprised of endothelial cells would help enhance their angiogenic potential and that
patterned cord geometry would be preserved upon implantation and subsequent vessel
formation in vivo. More broadly, we hypothesized that the implantation of patterned EC
cords could be used to control the architecture of engineered vasculature in vivo.
While effective in demonstrating a proof of concept, use of the first-generation
device for creating EC cords in extensive studies of vascularization was prohibitively
time consuming, required large numbers of cells (> 6 million per device), and yielded
cords that were limited in length (< 1 cm). To overcome these limitations, we designed,
fabricated and optimized a second-generation system for producing and removing EC
cords (Fig. 2.3). Fabrication of the new devices utilized a double-casting technique to
generate microchannels with surrounding flat regions within a PDMS well rather than
relying on a separate gasket (Fig. 2.3A, B). The second generation device was designed
to enable generation of larger numbers of cords using fewer cells (2 million per device).
The new device configuration allowed for cords to be easily removed from the
underlying PDMS template and embedded within other ECM materials to generate
implantable tissue constructs. The larger areas of cords could later be cut or ‘punched
out’ with a biopsy punch in preparation for implantation. Overall, the redesign resulted in
a twelve-fold reduction in the number of cells required to generate an implantable tissue
construct.
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Figure 2.3. First- and second-generation PDMS devices for generating cords. (A)
Process flow describing technique for fabricating first-generation device for
generating cords. (B) Process flow describing technique for fabricating secondgeneration devices for generating cords. Macroscopic images of final devices are
shown in bottom panels. (bars: 10 mm)

The complete redesign of the device required several optimizations to techniques
for generating cords. First, treatment of the PDMS with Pluronic F-127 required
modification. Pluronic, a nonionic, surfactant polyol, is used to render the surface of
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PDMS hydrophilic, making it largely non-adhesive to proteins and cells (M.-H. Wu,
2009). Here, a Pluronic treatment that is too mild will prevent proper cord formation by
allowing cells to adhere and migrate on the PDMS surfaces. Conversely, a Pluronic
treatment that is too harsh will render the PDMS surfaces almost entirely non-adhesive
causing the cords to float out of the microchannels upon addition of growth medium.
Through empirical tests, we determined that proper Pluronic treatment that achieves the
correct balance of adhesive cues is obtained by exposing the PDMS templates to a 0.02%
(w/v) Pluronic F-127 solution for 10 minutes. While we found that decreasing the
concentration to below 2x10-5 % was required to observe any effects of decreased
concentration, the length of Pluronic treatment had a significant impact on its effect.
Additionally, it should be noted that the negative PDMS masters from which the final
devices are cast could be reused no more that three times. After three casts, we observed
that the resulting devices were more adhesive to collagen and cells despite treatment with
Pluronic. Due to the double casting process, devices cast more than three times also
began to exhibit defects in the walls of the microchannels.
Given the larger volume of collagen within the microchannels in the secondgeneration device, application of the collagen and polymerization times also required
optimization. To prevent possibly confounding results and limit the scope of our studies,
we chose to fix the collagen concentration at 2.5 mg/ml. The design of the secondgeneration device, which included flat regions that surrounded the microchannels,
allowed for simple dewetting of the collagen by tilting the device and aspirating excess
collagen mixture. Proper Pluronic treatment was found to be critical for this dewetting
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step. In addition, the time required for the polymerization of the collagen required a
balance between ensuring that the gel has fully formed and preventing too much drying
of the sample, which led to cell death. Through a series of optimizations, we found that
inverting the sample for 5 minutes over a bath of water during polymerization achieved
the correct balance of gelation time and humidity and resulted in viable cords. Additional
complexity is introduced by the technique used when adding growth medium to the
polymerized cords immediately prior to culture. Upon methodically employing a variety
of techniques, we determined that allowing large drops of medium to fall onto the
microchannels yielded the best results. Briefly, five drops of growth medium are first
dispensed into the center and four corners of the microchannels from a height of several
millimeters. Subsequent drops are dispensed in a similar manner into the regions between
those already placed onto the substrate. As the second set of drops is introduced, the
growth medium accumulates into a larger pool that covers the entire area of
microchannels containing cords. The final volume of medium is brought up to 750 µl by
dispensing slowly into one of the corners of the device. Importantly, extreme care must
be taken during this process not to dislodge the cords from the microchannels during
these final steps.
Lastly, additional development of the technique was required to remove the cords
into a PDMS-free ECM. While collagen was used in the first-generation device, we used
fibrin for in vivo studies in order to take advantage of its proangiogenic effects (Hall,
Baechi, & Hubbell, 2001; Lesman et al., 2011). After experimentation with a variety of
methods, we found that cutting away of the surrounding PDMS well and inversion of the
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microchannels containing cords onto a pool of pre-polymerized fibrin yielded the best
results. Use of a PDMS gasket helps to ensure that constructs with a controlled thickness
are generated. After 15 minutes of polymerization, the sample can then be flooded with
PBS, which allows the positive buoyancy of the PDMS to help lift it off of the underlying
fibrin matrix. Several layers of cords can be stacked on top of each other to generate
more complex geometries. In the final step, an additional layer of fibrin is added to
encapsulate the exposed surface of the cords. The large area of the microchannels allows
for 6 mm discs to be generated, which are suitable for implantation into mice (Fig. 2.4).
A schematic of the process for generating cords using the second-generation of devices is
shown in Figure 2.5.

Figure 2.4 Removal of EC cords into fibrin (A) Previous methods of cord removal
resulted in cords with disrupted morphology. (bar: 250 µm) (B) Inversion of
microchannels onto gaskets containing fibrin results in a preserved cord geometry.
Gels can be cut into 6 mm modular constructs suitable for implantation into mice.
(bar: 500 µm) (C) Controlled method for removal of cords allows for stacking several
devices to generate more complex geometries. (bar: 200 µm)
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Figure 2.5 Schematic of process used to generate EC cords using secondgeneration PDMS devices. Design modifications including increased
microchannel area and incorporation of flat border regions allow for the
removal and generation of larger cords, which are amenable to implantation
into mice.

2.2.2 Screening cell types and coculture ratios for use in cords
A variety of endothelial cell types have been used in tissue engineered vascularization
strategies (Au, Daheron, Duda, Cohen, Tyrrell, et al., 2008a; Koike et al., 2004; Melero41

Martin et al., 2008; Traktuev et al., 2009). Here, we screened the ability of HUVECs and
eEnd.2 cells to organize into networks when cultured within collagen gels in vitro. Given
our hypothesis that established cell-cell contacts might help enhance the angiogenic
effect of implanted cords, we attempted to choose a cell mixture capable of extensive
cell-cell interactions and networking behavior. We first tested the eEnd.2 murine
embryonic endothelial cell line by culturing the cells in a 2.5 mg/ml collagen gel for 4
days (Williams, Courtneidge, & Wagner, 1988). While these cells exhibited localized
networking behavior, significant clumping was observed and large increases in cell
number indicated high rates of proliferation (Fig. 2.6). This high rate of proliferation in
3D led us to conclude that the eEnd.2 cell type was a poor candidate for use in a
vascularization strategy whose goal it is to generate stable vessels in vivo. Next, we tested
human umbilical vein endothelial cells (HUVECs), a primary endothelial cell type
commonly used in angiogenesis and tissue engineering studies, for their ability to form
networks and extensive cell-cell contacts. After 4 days in culture within collagen gels,
these cells exhibited limited networking behavior (Fig. 2.7). Proliferation, however,
seemed significantly lower than in the eEnd.2 cells.
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Figure 2.6 Networking behavior of e.End2 cells in collagen gels. Brightfield
imaging of eEnd.2 cells cultured in 2.5 mg/ml collagen for 4 days at
concentrations of 1x105 cells/ml (A), 5x105 cells/ml (B), 1x106 cells/ml (C) and
2x106 cells/ml (D) shows localized networking (clumping) and suggests extensive
proliferation. (bars: 100 µm)
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Figure 2.7 Networking behavior of HUVECs in collagen gels. Brightfield
imaging of HUVECs cultured in 2.5 mg/ml collagen for 4 days at concentrations
of 1x105 cells/ml (A), 5x105 cells/ml (B), 1x106 cells/ml (C) and 2x106 cells/ml
(D) shows limited networking or cell-cell interactions. (bars: 100 µm)

C3H10T1/2 is a murine cell line of mesenchymal origin with demonstrated
potential to differentiate into pericytes and promote vessel maturation (Hirschi,
Rohovsky, & D'Amore, 1998; Koike et al., 2004). We screened the behavior of HUVECs
in the presence of varying ratios of 10T1/2s when cultured within collagen gels in vitro.
Previous results indicated that a density of 1x106 HUVECs/ml yielded a cell dense
environment that did not lead to clumping. Thus, we included 10T1/2s in culture with
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HUVECs at ratios of 1:50, 1:30 and 1:10 (10T1/2s to HUVECs) while maintaining the
total cell number at 1x106 cells. We assessed the behavior of this cell mixture after 4 days
in culture in a 2.5 mg/ml collagen gel (Fig. 2.8). Evidence of networking and increased
cell-cell contacts was increased when 10T1/2s were added to the HUVEC/collagen
mixture. Increased 10T1/2 ratios seemingly led to increased networking behavior. At
higher concentrations of 10T1/2s, some clumping was evident. Based on these
preliminary screens and existing studies, a ratio of 1:50 10T1/2s to HUVECs was
ultimately chosen for generating EC cords. Unless otherwise noted, this mixture of cells
was used throughout the remaining studies described in this dissertation.
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Figure 2.8 Networking behavior of HUVECs + C3H10T1/2 cells collagen gels.
Brightfield imaging of 1x106 HUVECs cultured in 2.5 mg/ml collagen for 4 days
at with no 10T1/2s (A), 1:50 (B), 1:30 (C) or 1:10 (D) ratios of 10T1/2s to
HUVECs. (bars: 100 µm)

2.2.3 In vitro characterization of endothelial cell cords
Having created a robust platform for generating cords, we performed several
characterizations to better understand the composition of cords and the mechanics and
cellular dynamics of the cord formation process. First, time-lapse imaging of cells
fluorescently labeled with calcein revealed that the small population of 10T1/2s remained
randomly distributed within the mostly HUVEC cords throughout the contraction process
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(Fig. 2.9A,B). Hematoxylin and eosin (H&E) and sirius red staining of fully contracted,
paraffin embedded cords suggested that some clustering and wrapping of cells around a
core of compacted collagen might also occur (Fig. 2.9C). These occasional clusters,
however, were randomly distributed along the length of the cords.

Figure 2.9 Relative distribution of HUVECs, 10T1/2s within collagen in EC
cords. (A) Combined phase and fluorescence images of cord formation at 0
and 10 hours within PDMS microchannels (HUVECs: magenta, 10T1/2s:
green, bars: 50 µm). (C) Maximum intensity z-projection of fluorescently
labeled HUVECs (magenta) and 10T1/2s (green) within fully formed cords
(bar: 50 µm). (bars: 20 µm).
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Once in culture, cords contracted to approximately 65% of their original diameter
over a period of 10-12 hours (Fig. 2.10). To verify that this contraction is driven by cells
exerting tractional forces against the surrounding ECM we treated cords with the myosin
IIa inhibitor blebbistatin or the RhoA inhibitor Y27632. When treated with these
inhibitors immediately after seeding, the cords remained in their uncontracted state (Fig.
2.10). Wash our of the inhibitors after 6.5 or 7.5 hours led to a rapid resumption of the
contraction process. Within 6 hours of wash out, the cords had contracted to
approximately 50-60% or their original diameter, which matched the contractility at 6
hours of cords treated with DMSO. These treatments confirmed our hypothesis that
RhoA and myosin-mediated cytoskeletal tension are required for cord contraction.
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Figure 2.10 Cytoskeletal tension is required for cord contraction in vitro. (A)
Time lapse imaging depicting cord formation in samples treated with vehicle,
blebbistatin, or Y27632 (bars: 50 µm). (B) Quantification of cord contraction
reveals rapid increase in contraction after wash out of cytoskeletal tension
inhibitors.
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To determine whether the presence of 10T1/2 cells affected the dynamics of cord
contraction, we generated HUVEC only cords and compared their contraction rate to that
of HUVEC + 10T/1/2 cords (Fig. 2.11). Given the contractile nature of mural cells in
vivo, we predicted that cords containing 10T1/2s would contract more rapidly or to a
higher degree than those containing HUVECs alone. Interestingly, both cord types
exhibited similar contraction rates, suggesting that the contribution from 10T1/2 cells was
negligible or not detectable in the presence of a high number of HUVECs.
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Figure 2.11 Contribution of C3H10T1/2 cells to cord contractility (A) Time-lapse
phase contrast imaging shows contracting cords containing HUVECs + 10T1/2s
or HUVECs only. Dashed lines delineate cord boundaries. (bars: 50 um) (B)
Quantification of cord diameter indicates that the inclusion of 10T1/2 cells in
cords has no significant impact on their contractility dynamics (error bars: sem,
n=2).
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To demonstrate the potential of using EC cords to pattern vasculature into a
variety of geometries, we attempted to generate cords with a range of diameters and
shapes. While in our previous work we demonstrated that varying collagen concentration
could be used to alter final cord diameter, this approach is limited to a small range of
diameters (Raghavan, Nelson, Baranski, Lim, & Chen, 2010a). Here, we chose to
maintain a consistent collagen concentration while varying the PDMS microchannel
width. To maintain a 1:1 aspect ratio for the various microchannel widths, separate
wafers with matching heights were fabricated for each width. For cords with varying
geometries, 150 µm wide and 150 µm deep microchannels were used. Several minor
optimizations were necessary when generating cords of varying diameters. Cords smaller
than 100 µm yielded a much-reduced volume of collagen within the PDMS
microchannels than the typical 150 µm cords. Because such a small volume of collagen
polymerized and dried out much more quickly, the polymerization time was reduced to
just 2-3 minutes for smaller cords. In addition, the smaller microchannels exhibited a
tendency to trap bubbles. After experimentation with a variety of techniques including
vacuum degassing, we found that using a 1:20 rather than the typical 1:10 w/w ratio of
PDMS base to curing agent resulted in much softer PDMS that could be more vigorously
‘scraped’ without damage to help remove trapped bubbles. Lastly, the technique for
adding growth medium to the various cord shapes required adjustment. We found that in
order to prevent the patterned cords floating out of the microchannels, it is necessary to
add growth medium in a particular sequence: first to the areas most prone to damage such
as vertices or junctions, second to the exposed ends of cords, and third to the remainder
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of the cords and surrounding flat regions. These modifications allowed us to successfully
generate cords with diameters that ranged from 25 µm to 500 µm (Fig. 2.12A) and a
variety of architectures (Fig. 2.12B).

Figure 2.12 Generation of EC cords with varying diameters and geometries. (A)
Phase contrast images of cords of varying diameters removed from PDMS
templates and embedded in fibrin. (bars: 150 µm) (B) Brightfield images of
cords with branching geometries removed from PDMS templates and embedded
in fibrin. (bars: 1 mm)
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2.3 Vascularizing engineered tissues in vivo via implantation of
endothelial cell cords
2.3.1 Development of in vivo implantation model
To enable us to study the capability of EC cords to induce vascularization in vivo, we
tried several surgical implantation models. We first attempted implantation of tissue
constructs (fibrin gels containing EC cords) subcutaneously onto the backs of athymic
mice. We found that constructs that were not sutured into place would never engraft
properly into the host tissue. Seemingly, the unanchored constructs were always mobile
within the subcutaneous space while the mice were active, which prevented them from
engrafting. Next, we attempted to suture the tissue constructs in place to the subcutaneous
tissue (hypodermis). While this approach effectively immobilized the constructs in place
and seemed to improve engraftment, no vascular response was observed (Fig. 2.13A). We
next attempted intra- and perimuscular implantation of our tissue constructs on the flanks
of athymic mice. Both of these surgical sites required suturing to keep the construct
properly immobilized. Neither site, however, resulted in a visible vascular response.
Lastly, we implanted tissue constructs containing EC cords by suturing them directly to
the parametrial fat pad within the intraperitoneal cavity. Gross observation of constructs
harvested 5 days post implantation (PI) suggested proper engraftment and potential
vascularization (Fig. 2.13). While observations of the gross anatomy of resected tissue
constructs provided insights into the lack or presence of a response, histological
techniques including hematoxylin and eosin (H&E) staining were used to verify the
initial observations. Indeed, H&E staining of tissue constructs implanted adjacent to the
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parametrial fat pad strongly suggested that blood was present within or near the
implanted cords (Fig. 2.14).

Figure 2.13 Gross anatomy of tissue constructs resected 5 days post-implantation
(A) Tissue construct (dashed line) sutured to the hypodermis remained
immobilized, but failed to become vascularized. (bar: 250 µm) (B) Tissue
constructs sutured to the parametrial fat pad and exhibited a reddish appearance,
which was suggestive of vascularization. (bar: 200 µm) (C) The patterns visible
within these constructs sometimes mimicked those of the implanted cord
architecture (arrowheads). (bar: 100 µm)
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Figure 2.14 Early evidence of blood in implanted tissue constructs containing EC
cords. H&E staining suggesting presence of blood in tissue constructs implanted
adjacent to the parametrial fat pad. Fibrin gels containing EC cords directly
sutured to the parametrial fat pad and resected 5 days PI. Arrowheads denote
cords with evidence of red blood cells in transverse (left panel) or longitudinal
cross section. (bars: 100 µm)

While histological examination of tissue constructs implanted adjacent to the
fat pad indicated the presence of blood within cords, the overall architecture of the
constructs and cords contained within was poorly preserved. This inability to
maintain the originally patterned architecture within the tissue constructs made it
difficult to properly assess the vascular response within the cords. To better preserve
the geometry of the tissue constructs, we devised several approaches that utilized stiff
and biocompatible materials to prevent the implanted constructs from losing their
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shape upon implantation. First, we created our tissue constructs atop a thin (1 mm)
layer of PDMS. The combined PDMS and fibrin gel with cords were cut into 6 mm
discs using a biopsy punch. Small (0.75 mm) holes were punched near the periphery
of the PDMS to allow for sutures to be passed through the structure for attaching to
host tissue (Fig 2.15A). Without these holes near the discs’ periphery, passing a
suture needle through the PDMS discs led to tearing. This approach successfully
maintained the shape/geometry of the constructs upon implantation. However, we
found that the PDMS discs engrafted to the host adipose tissue making their removal
without disrupting the implanted constructs extremely difficult. Because PDMS
cannot be sectioned resecting the entire fat pad and implanted construct with the
PDMS still attached would prohibit any subsequent histological analysis. Given these
complications with PDMS, we next attempted to use a polypropylene mesh as a
backing material for the tissue constructs. We cut small squares of mesh material (~1
cm2) and embedded them in fibrin. This procedure was performed atop a Pluronictreated PDMS-coated petri dish to aid in the detachment of the fibrin prior to
implantation. We next inverted cords onto the mesh/fibrin layer and removed them as
before. The resulting assembly consisted of a layer of cords positioned immediately
atop the polypropylene mesh with the entire assembly encased in fibrin (Fig. 2.15B).
While it was possible to section the polypropylene mesh, we found that the mesh
filaments prevented any imaging of the embedded cords. To enable potential
intravital imaging of our tissue constructs, we utilized a ‘donut’-shaped
polypropylene mesh (Fig. 2.15B). These donut-shaped meshes were generated using
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heated cork borers. The smooth outer edge facilitated their manipulation during
surgery, while the inner hole would allow for direct imaging of the cords in the
future. Use of a mesh material allowed for the needle and sutures to be passed directly
through the periphery of the mesh without any further modifications during
implantation (Fig. 2.15D).

Figure 2.15 Development and implantation of a backing structure implantable
tissue constructs. (A) Cords embedded in fibrin atop a PDMS backing structure
containing holes for suturing. (bar: 1 mm) (B) Cords atop polypropylene mesh
embedded in fibrin. Mesh structure allowed for suture and needle to be passed
through the material without any additional modifications. (bar: 2 mm) (C) Cords
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atop ‘donut-shaped’ mesh embedded in fibrin. Inner hole facilitated imaging of
cords while smooth outer edge aided in implantation. (bar: 1 mm) (D) Mesh ring
sutured sutured atop the parametrial fat pad in preparation for implantation. (bar:
4 mm)

The polypropylene mesh incorporated into our design could be readily sectioned
and successfully preserved the geometry of the implanted tissue constructs. These
refinements to the implantation model allowed us to more thoroughly investigate whether
cords were eliciting a vascularization response in vivo. H&E and sirius red staining of
paraffin embedded tissues resected after 7 days indicated the presence of collagen-rich
structures spatially organized in a pattern that mimicked the original position of the
implanted cords (Fig. 2.16A). Higher magnification suggested the presence of blood in
cell-rich regions that surrounded the periphery of the cords (Fig. 2.16B).
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Figure 2.16 Preservation of geometry and presence of blood in EC cords resected
7 days post-implantation. (A) H&E and sirius red staining of cord-containing
tissue constructs resected after 7 days in vivo suggests that original cord geometry
was preserved upon implantation. Arrowheads indicate location of cords. (bar: 50
µm) (B) Higher magnification indicates areas of blood around the periphery of
cords. (bars: 10 µm)

Our first analyses of vascularization within implanted EC cords relied solely on
traditional histological stains such as H&E, sirius red and fast green. These stains were
performed on sections cut from paraffin embedded tissue constructs. To facilitate
immunohistochemical staining, we attempted to cut frozen sections of tissue constructs
that were resected 5 days PI, briefly fixed and cryoembedded (Fig. 2.17). The cutting of
tissue constructs via frozen section techniques, however, proved extremely difficult due
to the heterogeneous nature of the tissues. While the optimal cutting temperature of the
fibrin tissue constructs was relatively high (-17 oC), the temperature required for properly
cutting the surrounding adipose tissue was extremely low (-35 oC). This incompatibility
60

in cutting temperatures resulted in smearing of the adipose tissue at higher temperatures
and defects (likely due to cracking) in the fibrin tissue constructs at lower temperatures.
Given these difficulties in cutting frozen sections, all immunohistochemical analyses
described in this dissertation relied on paraffin embedded histological techniques, which
yielded significantly improved preservation of tissue morphology (Fig. 2.17B).

Figure 2.17 Frozen sectioning of tissue constructs. (A) Low magnification of H&E
stained frozen section resected 5 days PI. Sections cut at low temperatures exhibited
defects in the fibrin gels, while cutting at higher temperatures led to smearing of
adipose tissue. Arrowheads indicate areas of cutting defects. (B) Sections cut from
paraffin embedded tissue constructs showed no signs of defects and appeared to
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exhibit improved preservation of morphology (tissue construct implanted without
mesh support). (bars: 500 µm)

2.2.2 Implantation of endothelial cell cords drives formation of mature capillaries in
vivo
To confirm whether implantation of endothelial cell cords resulted in the formation of
blood vessels, we harvested tissue constructs at days 3, 5, 7, 14 and 28 post implantation
(PI). H&E staining suggested the presence of red blood cells (RBCs) within cords as
early as 3 days PI (Fig. 2.18A) with larger pools of blood also evident at both 3 and 5
days PI. These large areas of blood, suggestive of leaky vasculature, were replaced over
time by smaller, vessel-like structures that persisted until 28 days PI. Sirius red/fast green
staining indicated the persistence of a collagen core within cords for the duration of the
entire time course (Fig. 2.18B). These collagen-rich areas showed no signs of degradation
even at 28 days PI, and blood and surrounding cells were largely localized to the
periphery of cords. To verify the presence of RBCs and endothelial cells of human origin,
we performed immunohistochemical staining for Ter-119, an erythroid cell marker, and
human-specific CD31 (Fig. 2.18C). Positive Ter-119 staining confirmed the presence of
RBCs in all time points, and patterns matched those previously observed with H&E
staining. Human-specific CD31 staining confirmed that the RBC-containing structures
were blood vessels comprised of endothelial cells of human origin. These vessels
appeared large and poorly organized at days 3 and 5 PI, but rapidly organized into
smaller, lumenized capillaries as early as 7 days PI and persisted until at least 28 days PI.
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Staining for alpha smooth muscle actin (α-SMA) revealed the presence of α-SMApositive cells in a perivascular localization as early as day 3 (Fig. 2.18D). As nascent
vessels reorganized into smaller capillaries, these α-SMA-positive cells became more
tightly associated with adjacent endothelial cells indicating that they had adopted a
pericyte phenotype.

Figure 2.18 Implanted EC cords drive formation of mature capillaries. (A) H&E
staining of tissue constructs containing EC cords resected at days 3, 5, 7, 14 and 28
PI suggests presence of blood within vessels that organize into small capillaries
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(arrowheads) by day 7 (bar: 10 µm). (B) Sirius red/fast green staining confirms
presence of collagen within implanted cords. (bar: 10 µm) (C) Ter-119 (red) and
human-specific CD31 (green) staining identify RBCs and ECs, respectively. All
areas containing RBCs also exhibited neighboring human ECs suggesting that
vessels were patent (bar: 10 µm) (D) α-SMA staining (magenta) and higher
magnification indicate the presence of α-SMA-positive cells with a perivascular
localization. These cells appeared more tightly associated with capillaries at days 14
and 28 PI. (bar: 20 µm)

Quantification of vessels and blood in H&E stained sections further suggested the
presence of mature capillaries within implanted tissue constructs (Fig. 2.19A). Namely,
three trends were observed between days 5 and 7 PI: 1) the area of blood within cords
decreased from approximately 65% to 25% of total cord area; 2) the number of vessels
within cords increased from approximately 1.5 to 4.0; and 3) the average vessel diameter
decreased from approximately 30 µm to 7 µm. All trends continued until at least 28 days
PI and suggest that the cords quickly anastomose (day 3 PI) with the host vasculature to
form nascent, leaky vessels that form lumens and reorganize into smaller, more numerous
and mature capillaries (Fig. 2.19B).
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Figure 2.19 Quantification of the vascularization response (A) Quantification of
blood area showed a sharp decrease in areas containing blood between 5 and 7 days
PI. The average number of vessels per cord increased steadily after day 7, while the
size of the vessels decreased and stabilized at a size of approximately 7.5 um after
day 5 PI (*: p < 0.05 for comparison of days 7, 14 and 28 vs. 3 and 5 in blood area
measurements and vessel diameter measurements, days 14 and 28 versus 3, 5 and 7 in
vessel number measurements, error bars: sem, n ≥ 5). (B) Timeline with qualitative
description of vascularization trends.

In addition to immunohistochemical techniques, we attempted to better track
implanted endothelial cells by utilizing fluorescently labeled HUVECs. The labeled cells
included HUVECs that were stably transduced with H2B:GFP via a lentiviral vector and
commercially available cells that were also transduced using lentivirus (Angio65

Proteomie). We found that either population of labeled HUVECs failed to induce
vascularization in vivo when patterned into cords and implanted. These cells spread to
cover a larger surface area in culture and proliferated slower than unlabeled cells. Cords
generated using the labeled HUVECs also appeared ‘frayed’ in appearance and
contracted to a lesser degree than those generated with control cells. Given these
abnormalities and lack of a vascularization response, we concluded that these means of
labeling HUVECs placed too high of a metabolic burden on the cells and prevented them
from functioning normally in our system. Additionally, successful immunohistochemical
staining for human-specific CD31 (Fig. 2.18C,D) alleviated the need for labeled cells.
To gain additional insight into the mechanism of cord-host vessel anastomosis
and the composition of newly formed capillaries, we injected a cocktail of fluorescently
labeled human and mouse-specifc lectins via the tail vein (Fig. 2.20). Subsequent
Fluorescent imaging near the edge of implanted constructs following injection of a
cocktail containing Helix pomatia agglutinin (HPA)-AlexaFluor488 and Ulex europaeus
agglutinin I (UEA I)-TRITC indicated that perfused vessels extending beyond the
boundary of the cords within tissue constructs were of mouse origin (Fig. 2.20A).
Capillaries within the cords were comprised of a chimera of mouse and human
endothelial cells. Imaging of host adipose tissue confirmed the lack of cross reactivity
between UEA I and mouse vessels (Fig. 2.20B).
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Figure 2.20 Composition of vessels at graft periphery. (A) Staining of constructs
with mouse-specific (HPA) lectin revealed that vessels extending beyond the
boundary of the cords were of mouse origin and appeared connected to several
cord-associated capillaries (dashed line). Staining with human-specific (UEA-1)
lectin further showed that capillaires within cords exhibited a chimeric
composition (arrowheads: mouse, arrow: human). (B) Imaging of surrounding
host adipose tissue confirmed the lack of cross reactivity between UEA I and
mouse vessels. (bars: 25 µm)

We next attempted to determine whether viable cells were a necessary for cord
vascularization by implanting tissue constructs consisting of acellular fibrin gels, fibrin
gels containing HUVECs and 10T1/2s randomly seeded and precultured for 2 days, or
fibrin gels containing cords that had been ‘decellularized.’ To generate decellularized
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cords, we patterned cells into cords as usual and subsequently induced cell death via snap
freezing, exposure to hypo- and hypertonic solutions, and dissolution of the cell
membrane in CHAPS or SDS detergents. Live/dead stains revealed that CHAPS buffer
followed by 12 hours of PBS washing were most effective at removing cellular
components without disturbing the surrounding matrix.
H&E staining of acellular fibrin gels indicated that they remained absent of cells
and showed no evidence of blood at 7 days PI (Fig. 2.21A). In gels containing
precultured HUVECs and 10T1/2s, small areas of blood near the periphery of the
constructs suggested the formation of a small number of capillaries (Fig. 2.21B). Staining
of ‘decellularized’ cords indicated the presence of small nuclei or DNA fragments near
areas of collagen matrix, but no blood was evident (Fig. 2.21C). Overall, none of these
control conditions yielded a vascularization response comparable to that seen upon
implantation of viable EC cords.

Figure 2.21 Cells are required for vascularization (A) H&E staining of acellular
fibrin gel resected 7 days PI indicates lack of cells and blood. (B) H&E staining of
fibrin gel containing mixture of HUVECs and 10T1/2s resected 7 days PI. Several
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areas suggest the presence of RBCs within capillaries. (C) H&E staining of fibrin
gel containing decellularized EC cords resected 5 days PI. Hematoxylin staining
suggests the presence of several small nuclei or DNA fragments, but no blood.
(bars: 25 µm)

The presence of 10T1/2 cells within cords had no effect on their contraction in
vitro (Fig. 2.11). Here, we tested whether varying the relative proportions of 10T1/2s and
HUVECs within implanted cords had an effect on the size of capillaries that form upon
implantation. At 5 days PI, however, cords containing 2:1, 1:5, or 1:50 ratios of 10T1/2s
to HUVECs did not seem to impact capillary diameter (Fig. 2.22). Given the known
contributions of 10T1/2s to the vascularization process (Hirschi et al., 1998; Koike et al.,
2004) and the lack of an observable effect upon their implantation in various ratios, we
performed the remainder of studies with the originally established 1:50 ratio of 10T1/2s
to HUVECs.
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Figure 2.22 Effect of varying 10T1/2 to HUVEC ratios on in vivo capillary
formation. No observable differences were seen in capillary size upon implantation
of cords containing 2:1 (A, longitudinal cross-section), 1:5 or 1:50 10T1/2 to
HUVEC ratios after 5 days in vivo. (bars: 25 µm)

To determine whether the diameter of the implanted cords could impact the size
of the resultant capillaries, we implanted tissue constructs containing cords with 50 and
500 µm diameters (Fig. 2.23). Cells within the smaller cords were distributed randomly
around the collagen core and contained pools of blood that appeared smaller than
previously seen (Fig. 2.23A). Upon implantation of larger cords, the pools of blood
appeared similar in size to those observed upon implantation of 150 µm cords, and the
cells appeared localized to one side of the collagen core (Fig. 2.23B). Because the pools
of blood observed in 150 µm cords reorganized into smaller capillaries after 7 days in
vivo, we concluded that the same phenomenon would be observed in the 500 µm cords
implanted here. All subsequent EC cord experiments described in this dissertation
utilized 150 µm cords.
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Figure 2.23 Effects of cord diameter on vascularization in vivo. H&E staining of
tissue constructs containing 50 (A) and 500 µm (B) diameter cords resected 5
days PI. Smaller cords resulted in formation of small pools of blood at the
periphery of the collagen core. Cells in the larger cords appeared localized to one
side of the collagen core and indicated the presence of pools of blood similar in
size to those seen upon implantation of 150 µm cords. (bars: 25 µm)

2.2.3 Implantation of patterned endothelial cell constructs yields a perfused in vivo
vasculature with conserved geometry
Networks of implanted endothelial cells and fibroblasts can rapidly anastomose with the
host circulation (X. Chen et al., 2010). To confirm that capillaries formed upon
implantation of EC cords had anastomosed with the host vasculature, we performed
injections of FITC-dextran via the tail vein at day 14 PI. Fluorescent imaging revealed
the presence of a perfused network of capillaries with an architecture recapitulating that
of the implanted cords (Fig. 2.24A,B middle panels). Capillaries spanned the entire
length of the tissue constructs, and sprouts between adjacent capillaries within cords and
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between capillaries in neighboring cords were also evident. Histological examination of
tissue constructs resected 7 days PI additionally confirmed the presence of these sprouts
and capillaries spanning the region between adjacent cords (Fig. 2.25). FITC-dextran
injections of mice implanted with fibrin gels containing randomly seeded HUVECs and
10T1/2s did not result in comparable patterning of the vasculature and indicated that
perfused vessels were present only near the periphery of implanted constructs (Fig.
2.24A,B middle panels). To investigate whether vascular architecture can be spatially
patterned, we implanted tissue constructs that contained cords patterned into a Y-shaped
topology (Fig. 2.24A, right panel). FITC-dextran injection 14 days PI indicated that these
constructs resulted in the formation of vessels that anastomosed with the host vasculature
and recapitulated the geometry of the implanted cord pattern (Fig. 2.24B, right panel).
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Figure 2.24 Perfusion with host blood and patterning of in vivo vasculature. (A)
Brightfield images of non-implanted tissue constructs containing randomly seeded
HUVECs and 10T1/2s, parallel EC cords or EC cords patterned into a Y-shaped
topology (bars: 250 µm, 500 µm, 500 µm) (B) Confocal imaging following FTICdextran injection via the tail vein shows vascular architecture following
implantation of the tissue constructs shown in A. (bars: 100 µm)
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Figure 2.25 Capillary sprouting between adjacent cords.
H&E staining of EC cords in longitudinal cross-section
reveals presence of capillaries between adjacent cords
(arrow). Arrowheads indicate locations of cords. (bar: 25 µm)

2.2.4 Patterned vasculature within engineered hepatic tissues maintains hepatocyte
function
Improved vascular organization enhances the integration of engineered and host tissues
(Koffler et al., 2011). To test the ability of patterned EC cords to vascularize engineered
tissues and improve their function in vivo, we generated tissue constructs that contained
patterned EC cords and aggregates of primary rat liver hepatocytes (Fig. 2.26A). A
lentiviral vector was used to transduce the hepatocytes to express luciferase under control
of the albumin promoter. Bioluminescence imaging over 20 days following implantation
revealed that hepatocyte constructs containing cords exhibited significantly higher levels
of albumin promoter activity for at least 20 days (Fig 2.26C). Histological examination
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revealed clusters of aggregates adjacent to vessels containing blood and deposits of
collagen mimicking those previously found in the cords (Fig. 2.26B). Sirius red/fast
green staining suggested that collagen previously present in the EC cords had been
largely degraded and dense areas of elastin-rich matrix had been deposited by the
hepatocyte aggregates. Immunofluorescent staining for Ter-119 and arginase 1, a
hepatocyte marker, confirmed the presence of blood in areas directly adjacent to
hepatocyte aggregates. These staining patterns suggested that the implanted hepatocytes
remained viable for at least 20 days in vivo and had access to the host blood supply via
capillaries that formed as a result of the implanted cords.
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Figure 2.26 EC cords within engineered rat hepatic tissues improve function (A)
Three types of tissue constructs containing varying combinations of primary
hepatocyte aggregates and ECs were generated: 1) hepatocyte aggregates only, 2)
hepatocyte aggregates with randomly seeded HUVECs and 10T1/2s, and 3)
hepatocyte aggregates with EC cords (bar: 20 µm). (B) H&E and sirius red/fast
green staining revealed hepatocyte aggregates in close proximity to vessel-like
structures that contained blood. Immunostaining for Ter-119 (green) and arginase
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1 (red) confirmed the presence of RBCs in close proximity to viable hepatocyte
aggregates at 20 days PI. (bars: 25 µm) (C) Luciferase activity showed
significantly increased albumin promoter activity in the group of tissue constructs
containing patterned rat hepatocyte aggregates and EC cords at least 20 days PI (n
≥ 5, error bars: sem).

Next, we used primary human hepatocytes to investigate the effects of coimplanting patterned hepatocyte aggregates and EC cords. Histological analysis again
showed that hepatocyte aggregates co-implanted with EC cords had access to host blood
via adjacent capillaries (Fig. 2.27A). Luciferase imaging throughout the experiment
indicated that hepatocyte aggregates co-implanted with EC cords exhibited significantly
higher levels of albumin promoter activity (Fig. 2.27B). In an additional control
condition, we ligated the host vessels within the parametrial fat pad immediately
following implantation of the tissue constructs. Low albumin promoter activity within
this group further suggested that the observed increases in hepatocyte function were a
result of improved access to the vasculature rather than paracrine signaling alone.
Measurements of serum albumin at day 18 PI supported the trends observed via
luciferase imaging. Due to the low levels of serum albumin in all groups, however, these
results were not statistically significant.
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Figure 2.27 EC cords within engineered human hepatic tissues improve function.
(A) H&E and sirius red/fast green staining suggested that hepatocyte aggregates
were in close proximity to vessels that contained blood. Immunostaining for Ter119 (green) and arginase 1 (red) confirmed the presence of RBCs in close
proximity to viable hepatocyte aggregates at 18 days PI. (bars: 25 µm) (B)
Luciferase imaging revealed that constructs in the ‘no EC,’ ‘random EC,’ and
‘ligated’ control groups expressed similar levels of albumin expression.
Constructs containing aggregates patterned with EC cords performed significantly
better than control groups for at least 18 days PI (n ≥ 6, error bars: sem). ELISA
measurements suggested that serum albumin levels in all groups were comparable
to those measured via luciferase imaging.
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2.4 Materials and Methods
Cell culture
Primary human umbilical endothelial cells (HUVECs, Lonza) were cultured on 0.1%
gelatin-coated dishes in EGM-2 (Lonza). C3H10T1/2 cells [American Type Culture
Collection (ATCC)] were cultured in low glucose DMEM containing 10% fetal bovine
serum (Atlanta Biologicals), 100 units/mL penicillin, and 100mg/mL streptomycin
(Invitrogen). Primary human hepatocytes were cryopreserved and from a 1-yr-old female
Caucasian donor (Lot Hu8085; CellzDirect). Human hepatocytes were cultured in high
glucose DMEM (Cellgro) containing 10% fetal bovine serum (FBS; Gibco), 1% (vol/vol)
ITS supplement (insulin, human transferring, and selenous acid; BD Biosciences), 0.49
pg/ml glucagon, 0.08 ng/ml dexamethasone, 0.018 M HEPES, and 1% (vol/vol)
penicillin-streptomycin (pen-strep; Invitrogen). J2-3T3 fibroblasts (gift of Dr. Howard
Green; Harvard Medical School) were cultured in high glucose DMEM containing 10%
bovine serum, and 1% penicillin-streptomycin.
Primary rat hepatocytes (2 – 3 month old adult female Lewis rats; Charles River)
were isolated as described previously (A. A. Chen et al., 2011; Dunn, Tompkins, &
Yarmush, 1991; Seglen, 1976). Each rat was anesthetized and the portal vein was
cannulated. The liver was perfused with buffers followed by collagenase. Liver digest
was purified using Percoll centrifugation, and hepatocyte viability was typically 85 –
95% using trypan blue exclusion. Rat hepatocytes were cultured in high glucose DMEM
containing 10% (v/v) FBS, 0.5 U/ml insulin (Lilly), 7 ng/ml glucagon (Bedford
Laboratories), 7.5 µg/ml hydrocortisone (Sigma), and 1% pen-strep.
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Fabrication of PDMS templates and preparation of endothelial cell cords
Endothelial cell cords were micropatterned as previously described. Briefly, masters
were prepared by photolithographically exposing silicon wafers coated with SU-8
photoresist (Shipley) to develop channel patterns at a height of 150um. Liquid poly
(dimethylsiloxane) (PDMS) pre-polymer was poured onto the silicon masters and cured
to generate molded substrates. The PDMS substrates were sterilized with UV, and treated
with 0.01% Pluronic F127 for 10 minutes prior to use as culture substrates. HUVECs and
10T1/2s were suspended at a ratio of 50:1 in 2.5mg/mL liquid collagen (BD Biosciences)
and centrifuged into the PDMS channels. Excess unpolymerized collagen and cells were
removed by dewetting the surface of the substrate. The collagen was polymerized,
growth medium was added, and the constructs were incubated for 4-6 hours. The newly
formed cords were removed from the PDMS substrates by inverting onto a drop of
unpolymerized 7.5 mg/mL bovine fibrin (sigma). After the fibrin was polymerized at 37
oC, the constructs were submerged in PBS and the culture dish was gently agitated to
dislodge the PDMS. The PBS was aspirated and a second layer of unpolymerized fibrin
was added over the top and polymerized to fully encase the cords. The embedded cords
were cut with a 6 mm biopsy punch prior to implantation.

Decellularization of cord constructs
Cord constructs were prepared as described above and subsequently decellularized using
a solution containing 8 mM CHAPS, 1 M NaCl, 25 mM EDTA in PBS. During the
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decellularization process, constructs were submerged in the decellularization solution and
placed on an orbital shaker overnight. Excess cellular debris and detergent were then
removed by soaking the constructs in PBS on an orbital shaker for several hours. Wash
steps were repeated three times. The decellularized constructs were then cut with a 6 mm
biopsy punch as described above.

Construction of hepatic engineered tissues
To enable noninvasive imaging of hepatocyte function and survival in engineered tissues,
hepatocytes were transduced in suspension culture immediately after isolation (for rat
hepatocytes) or thaw (for human hepatocytes) with a lentiviral vector expressing firefly
luciferase under the human albumin promoter ((pTRIP.Alb.IVSb.IRES.tagRFP-DEST,
gift of Charles Rice, The Rockefeller University). Hepatocytes and J2 fibroblasts were
placed into Aggrewell micromolds overnight to form hepatic aggregates (average of 100
hepatocytes and 25 J2 fibroblasts per aggregate). Hepatic aggregates were removed from
Aggrewell templates and suspended randomly in 7.5mg/mL unpolymerized bovine fibrin
at a concentration of 15K/mL for the random aggregates condition. For the random
aggregates plus random HUVEC condition, hepatic aggregates were suspended randomly
in 7.5 mg/mL unpolymerized bovine fibrin at a concentration of 15k/mL along with 2
million HUVECs/mL and 10T1/2s at a 50:1 ratio. For the aggregates plus cords
condition, cords were embedded in 7.5mg/mL bovine fibrin containing randomly
suspended hepatic aggregates at a concentration of 15K/mL.
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In vitro imaging of endothelial cell cords
HUVECs were labeled with 5 ug/mL Calcein AM red-orange and 10T1/2s were labeled
with 5ug/mL Calcein AM (invitrogen) prior to trypsinization. PDMS substrates were
prepared and seeded as above. Cord contraction was imaged using an Eclipse
epifluorescent microscope. Final cord morphology was imaged using a Zeiss 710 laser
scanning confocal microscope. For measurements of cord contraction, cords were treated
with 20 µM blebbistatin or 25 µM Y27632 at 7.5 or 6.5 hours after seeding, respectively.
For in vitro imaging of hepatic constructs, Huh7.5 cells were labeled with 5
ug/mL calcein AM and placed into Aggrewell micromolds overnight to form aggregates
(approximately 100 cells per aggregate). Aggregates were removed from Aggrewell
templates and suspended in 7.5mg/mL unpolymerized bovine fibrin at a concentration of
15K/mL for the ‘No EC’ condition. For the ‘random EC’ condition, aggregates were
suspended in 7.5 mg/mL unpolymerized bovine fibrin at a concentration of 15k/mL along
with 2 million HUVECs/mL and 10T1/2s at a 50:1 ratio. HUVECs and 10T1/2s were
labeled with 5 ug/mL calcein red orange. For the ‘EC cords’ condition, cords were
embedded in 7.5mg/mL bovine fibrin containing randomly suspended hepatic aggregates
at a concentration of 15K/mL. Constructs were imaged using a Zeiss Axiovert 200m
microscope equipped with a Yokogawa spinning disk confocal unit.

In vivo implantation of cords
For cord only experiments, all surgical procedures were conducted according to protocols
approved by the University of Pennsylvania Institutional Animal Care and Use
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Committee. Eight week old female Nu/Nu athymic mice (Charles River) were
anesthetized using isoflurane and the constructs were sutured to the parametrial fat pad.
The incisions were closed aseptically, and animals were administered 0.1 mg/ml
buprenorphine every 12 hours for three days following surgery.
For hepatic engineered constructs, all animal procedures were approved by The
Committee for Animal Care in the Department of Comparative Medicine at
Massachusetts Institute of Technology. Immediately after engineered tissue fabrication,
NCr nude mice (Taconic) were anesthetized using isoflurane, and engineered tissues were
sutured to the mesenteric parametrial fat pad. For ‘cords + hepatocytes – excised’
animals, engineered tissue and attached mesentery were cut from the remainder of the
mesentery via an upstream excision such that the tissue and attached mesentery were no
longer directly connected to host circulation. The incisions were closed aseptically, and
animals were administered 0.1 mg/ml buprenorphine every 12 hours for three days
following surgery.

Bioluminescence imaging
For luminescence imaging, mice were injected intraperitoneally with 250 µL of 15
mg/mL D-Luciferin (Caliper Life Sciences) and then imaged using the IVIS Spectrum
(Xenogen) system and Living Image software (Caliper Life Sciences).
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Dextran perfusion, lectin perfusion and imaging
To preserve geometry during implantation, cords were embedded in a gasket cut from a
polypropylene surgical mesh (Davol). To visualize perfused vessels a 200uL solution of
20mg/mL fluorescein isothiocyanate (FITC)-labeled dextran (150 kDa) (Sigma) in PBS
was injected intravenously via the tail vein. To visualize mouse versus human vessels, a
200uL solution of 500µg/ml lectin from Helix pomatia agglutinin (HPA) conjugated to
Alexa 488 (Sigma), and 100µg/ml lectin from Ulex europaeus agglutinin (UEA-1)
conjugated to TRITC (Vector labs) in PBS was injected intravenously via the tail vein.
Animals were sacrificed and tissue was harvested from graft site immediately after
injection. Perfused vessels were subsequently imaged using a Zeiss 710 laser scanning
confocal microscope.

Tissue harvesting, processing and histology, and immunohistochemistry
Animals were sacrificed at various time points and tissue was harvested from the
intraperitoneal space. Explants were fixed in 4% PFA for 48 hrs at 4˚C , dehydrated in
graded ethanol (50-100%), embedded in paraffin, and sectioned using a microtome (6um)
for immunohistochemical staining. For gross visualization of tissue, sections were
stained with hematoxylin and eosin (H&E). For identification of cords composed
partially of collagen, sections were stained with Sirius red (collagen) and fast green (other
tissue elements).
For identification of vessels containing human endothelial cells, smooth muscle
cells, and erythroid cells, sections were first blocked using M.O.M. blocking reagent
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(Vector Labs) and normal goat serum and then immunostained using primary antibodies
against human CD31 (1:20; DAKO), Ter-119 (1:100; BD Biosciences), and smooth
muscle alpha-actin (1:100, Abcam). Signal was visualized after incubation with
secondary goat anti-IgG1-Alexa 555, goat anti-rat-Alexa 488, and donkey anti-rabbitAlexa 647 antibodies (Jackson ImmunoResearch). For identification of primary
hepatocytes adjacent to vessels containing red blood cells, sections were blocked using
normal donkey serum then incubated with primary antibodies against arginase-1 (ARG1,
1:400, Sigma) and Ter-119 and followed with species-appropriate secondary antibodies
conjugated to Alexa 488 and 555. Images were obtained using a Zeiss 710 laser scanning
confocal or Nikon 1AR Ultra-Fast Spectral Scanning Confocal Microscope.

Biochemical assays to assess hepatocyte function
Rat albumin in sampled media was quantified by enzyme-linked immunosorbent assay
(ELISA) using a rat albumin ELISA kit (Bethyl labs; sheep anti-rat albumin antibody at
1:100).

Statistical Analysis and Quantification of Vascularization Parameters
Quantification was performed on H&E sections of fully engrafted cord constructs. Blood
area was quantified by measuring the total area of tissue containing blood within a cord.
This measurements was normalized to average cord area to compensate for oblique
cutting angles. Vessel number was quantified by counting individual vessels within a
cord and was normalized to the average cord area. Vessel diameter was quantified by
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measuring the diameter of individual vessels within a cord. Sections for quantification
were chosen from the center of the constructs, and a minimum of 3 sections at least
150uM apart were quantified per cord. All data are expressed as the mean ± standard
error. Statistical significance was determined using the one-way ANOVA followed by
Tukey’s post hoc test for group comparisons.

2.5 Conclusions
In the work described here, we have developed a novel technique for generating
functional capillaries with spatially controlled geometry in vivo. Via adapting a
previously described system for patterning cells into organized cords, we have created a
strategy for embedding cords into implantable tissue constructs. The implantation of
these constructs into mice led to the formation of functional capillaries that become
perfused with blood within 3 days PI and remain stable and exhibit a mature phenotype
for up to 28 days PI. The capillary networks are perfused with host blood, contain vessels
that are largely comprised of implanted human cells, and exhibit a geometry that
recapitulates that of the implanted EC cords. Previous studies have suggested that the
ability to pattern vessels is essential for the function and proper engraftment of
engineered tissues ((X. Chen et al., 2009; Koffler et al., 2011)). Here, we have further
validated these findings by demonstrating that patterned EC cords used to vascularize
engineered hepatic tissues were capable of significantly improving function.
Future studies in vascular tissue engineering will require the development of
defined complex vessel architectures. Our data provide one of the first demonstrations of
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capillary network patterning in vivo and further suggest that this approach is a viable
strategy for vascularizing engineered solid tissues. We envision that the vascular
patterning technique described her will enable future studies toward the design of optimal
vessel architectures within a variety of tissue engineered contexts.
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CHAPTER 3: Proliferative regulation by adhesion and RhoGTPases in
smooth muscle cells is altered in idiopathic pulmonary arterial
hypertension

3.1 Introduction
Organotypic models provide a powerful tool for studying disease processes in vitro while
maintaining an added level of physiologic relevance that is not present in traditional
tissue culture models. While angiogenic models that rely on tubes or channels coated
with endothelial cells are common, more complex models of the arterial smooth muscle
compartment have been seldom used in mechanistic studies (Chrobak et al., 2006;
Zervantonakis et al., 2012). Niwa et al. and Fillinger et al. have previously described
techniques for generating bilayers of endothelial and smooth muscle cells (Fillinger et al.,
1997; Niwa et al., 2007). Here, we sought to generate an EC-SMC bilayer and utilize it in
the study of cells isolated from patients with pulmonary hypertension. Given a lack of
promising results, however, we continued with an investigation into the pathobiology of
pulmonary hypertension using traditional tissue culture models.
Pulmonary arterial hypertension (PAH) is a disease characterized by
hyperproliferation and remodeling within the small pulmonary arteries, which results in
increased blood pressure within the lung vasculature (Gaine & Rubin, 1998; Ikeda et al.,
2010; Rubin, 1997). In patients with PAH, the increased vascular resistance in the
pulmonary circulation places a greater workload on the heart and ultimately leads to right
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ventricular failure and premature death. Idiopathic pulmonary arterial hypertension
(IPAH), which occurs in the absence of identifiable risks, is particularly difficult to
diagnose (Chin & Rubin, 2008; Thyberg et al., 1990). Patients present with general
symptoms and diagnosis is only made after the exclusion of other heart and lung diseases
known to cause elevations in pulmonary arterial pressure. In patients with IPAH, the
estimated survival rates for patients receiving treatment at 1, 2, and 3 years are 83, 67,
and 58%, respectively (Aoyagi et al., 1997; Humbert et al., 2010; Jones & Rabinovitch,
1996; Monahan et al., 2007; Stouffer et al., 1998). Despite advances in the management
of IPAH and increases in survival rates, patients’ quality of life remains low and no
further treatments outside of the realm of lung transplantation currently exist.
Histological examination of pulmonary arterioles in patients with IPAH shows
neointimal thickening, pulmonary arteriolar occlusion, and plexiform lesions, suggesting
that IPAH is a primarily vasoproliferative disease with accompanying vasoconstriction as
well as catabolism and de novo synthesis of components of the extracellular matrix
(ECM) (Burridge & Chrzanowska-Wodnicka, 1996; Chin & Rubin, 2008; Farber &
Loscalzo, 2004; Guan & Shalloway, 1992; Humbert et al., 2004; Jones et al., 1997; Jones
& Rabinovitch, 1996; Kornberg, Earp, Parsons, Schaller, & Juliano, 1992; Pietra et al.,
1989). Studies into the mechanisms underlying abnormal PASMC proliferation in IPAH
have only recently begun, however, and this area of research still remains largely
unexplored (Chrzanowska-Wodnicka & Burridge, 1996; Ikeda et al., 2010; Lewis &
Schwartz, 1995; Richardson, Malik, Hildebrand, & Parsons, 1997; Roovers & Assoian,
2003).
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In vivo, the proliferation of SMCs is tightly regulated by many extracellular cues
including cell adhesion to the extracellular matrix (ECM), the presence of soluble growth
factors and cell-cell adhesion. In adult tissues, SMC proliferation is generally low and the
cells exhibit a differentiated phenotype that enables proper maintenance of vascular tone
and regulation of blood pressure. Upon injury and in the presence of the proper
extracellular cues, however, SMCs can undergo a switch to a more synthetic, highly
proliferative phenotype (Pirone et al., 2006; Thyberg et al., 1990). In this state, the
SMCs become highly proliferative and exhibit increased migration and ECM production.
Specifically, the production of ECM proteins including collagen, fibronectin, elastin,
tenascin-C, and proteoglycans increases, and the expression of adhesion molecules such
as integrins and cadherins is altered (Aoyagi et al., 1997; Danen, Sonneveld, Sonnenberg,
& Yamada, 2000; Jones & Rabinovitch, 1996; Monahan et al., 2007; Ren & Schwartz,
2000; Stouffer et al., 1998; Welsh et al., 2001). Given the presence of a pathologic
cellular microenvironment in the arteries of IPAH lungs, we sought to investigate
whether adhesive signaling might be altered in PASMCs isolated from IPAH patients and
whether this might impact proliferation of IPAH patient-derived PASMCs.
Adhesion-mediated proliferation in SMCs is facilitated by the binding and clustering of
integrins to ECM proteins, ultimately forming focal adhesions. Mature focal adhesions
serve dual roles as signaling hubs and as mechanical linkages between a cell and its
extracellular environment. Focal adhesion kinase (FAK) is a key effector in focal
adhesion signaling whose kinase activity is activated upon integrin ligation (Burridge &
Chrzanowska-Wodnicka, 1996; Guan & Shalloway, 1992; Kornberg et al., 1992; Pirone
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et al., 2006). FAK is involved in the development of focal adhesions allowing for cell
spreading and the establishment of cytoskeletal tension (C. Chen, Mrksich, Huang,
Whitesides, & Ingber, 1997; Chrzanowska-Wodnicka & Burridge, 1996; Lewis &
Schwartz, 1995; Richardson et al., 1997; Roovers & Assoian, 2003). Notably, FAK has
also been implicated as a key player in adhesion-mediated proliferative control via the
RhoA signaling pathway, which is downstream of cell adhesion to the extracellular
matrix (Chrzanowska-Wodnicka & Burridge, 1996; Pirone et al., 2006). Specifically,
FAK regulates the activity of the Rho GTPase RhoA, which is required for sustained
ERK signaling and cell cycle progression (C. Chen et al., 1997; Danen et al., 2000;
Raines, 2000; Ren & Schwartz, 2000; Welsh et al., 2001).
Herein, we investigated the proliferative control mechanisms at work in PASMCs
isolated from patients with advanced IPAH. We found that IPAH PASMCs showed
significantly increased proliferation in vitro as compared to normal controls. While
control cells exhibit a Rac-regulated proliferative control mechanism, IPAH cells appear
to be Rho- dependent. Additionally, IPAH PASMCs exhibit several abnormalities in
adhesion signaling including increased focal adhesion size, higher FAK phosphorylation
levels, and loss of spreading-dependent proliferative control. Inhibition of FAK restored
normal adhesion- mediated proliferation control suggesting that altered adhesion
signaling might underlie the abnormal proliferation of PASMCs in IPAH.
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3.2 Development of an organotypic arterial wall model
To generate an in vitro model of an arterial wall, we sought to create a bilayer structure
consisting of endothelial cells (intima) grown atop a layer of smooth muscle cells and
ECM (media). Treatment of SMCs with ascorbic acid leads to increased collagen
production, decreased proliferation, and increased expression of smooth muscle markers
(Arakawa et al., 2003; Niwa et al., 2007; Qiao, Bell, Juliao, Li, & May, 2009). By
stimulating bovine pulmonary arterial smooth muscle cells (bPASMCs) with ascorbic
acid, we first attempted to create an ECM rich layer of smooth muscle cells.
Immunofluorescent staining suggested that treatment with 50 µg/ml ascorbic acid of
bPASMCs cultured on fibronectin-coated glass increased expression of α-smooth muscle
actin and decreased proliferation (Fig. 3.1A). Further culture of these cells in the presence
of ascorbic acid, however, did not seem to affect their morphology or the rate at which
they reached confluence (Fig. 3.1B). Additionally, confluent cells appeared growth
arrested and did not continue proliferating to form a multilayered structure as expected.
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Figure 3.1 Ascorbic acid treatment of bPASMCs (A) Immunostaining indicated
that bPASMCs cultures treated with ascorbic acid exhibited increased α-SMA
expression (red) within 24 hours of seeding. Decreased numbers of nuclei (blue)
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also suggested that ascorbic acid treatment decreased proliferation. (bars: 20 µm)
(B) Time lapse phase contrast imaging over 8 days did not show any observable
differences in cultures of bPASMCs treated with ascorbic acid and control cells.
(bars: 50 µm)

We next attempted to seed a monolayer of endothelial cells atop confluent layers
of smooth muscle cells. We seeded bovine pulmonary arterial endothelial cells (BPAECs)
at a density of 100,000 cells/cm2 atop confluent layers of bPASMCs treated with ascorbic
acid (Fig. 3.2A, B). The bPAECs were labeled with CMTPX CellTracker dye and imaged
for 10 hours. While the bPAECs appeared to attach and remain viable, they did not
spread and proliferate to form a monolayer. Extended times in culture confirmed that the
bPAECs did not proliferate and appeared to invade the layer of bPASMCs underneath
and adhere to the glass substrate below. Seeding bPAECs at a higher density (200,000
cells/cm2) yielded similar results (Fig. 3.3A, B). The higher density of endothelial cells
present at the start of the experiment allowed for direct contact between neighboring
cells. While we had hypothesized that this presence of cell-cell contacts might stimulate
the bPAECs to remain as a monolayer, similar results to those utilizing the lower
concentration of bPAECs were observed.
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Figure 3.2 bPAECs (100,000 cells/cm2) grown atop a layer of bPASMCs.
Combined fluorescence and phase contrast imaging of 100,000 bBPAECs (red)
seeded onto a confluent layer of bPASMCs (unlabeled) that were either
untreated (A) or treated with 50 µg/ml ascorbic acid (B). bPAECs attached, but
remained rounded and failed to proliferate and form a monolayer. (bars: 100
µm)

95

Figure 3.3 bPAECs (200,000 cells/cm2) grown atop a layer of bPASMCs.
Combined fluorescence and phase contrast imaging of 100,000 bBPAECs (red)
seeded onto a confluent layer of bPASMCs (unlabeled) that were either
untreated (A) or treated with 50 µg/ml ascorbic acid (B). bPAECs attached, but
remained rounded and failed to proliferate and form a monolayer. (bars: 100
µm)

Given the failure of bPAECs to spread atop layers of bPASMCs, we sought to
generate a ‘reversed’ aortic wall model by culturing smooth muscle cells atop endothelial
cells. While such a model would be slightly less physiologically relevant, we
hypothesized that it might still be useful for testing a variety of physiologically relevant
96

phenomena in an in vitro setting. To create this ‘reversed’ arterial model, we seeded
bPASMCs onto a monolayer of bPAECs. Imaging of bPASMCs transduced with GFP via
an adenoviral vector cultured atop bPAECs treated with DiI-AcLDL, however, indicated
that the bPASMCs did not remain on the top surface of the endothelial monolayer (Fig.
3.4). Rather, the ECs and SMCs seemed to mix randomly and failed to create a
multilayered structure that might mimic arterial physiology.

Figure 3.4 ‘Reverse’ arterial wall model. 15um z-stack of bPASMCs
cultured atop a monolayer of bPAECs. bPASMCs were transduced with
GFP (green) via an adenoviral vector, bPAECs labeled with DiI-AcLDL.
X-Z (top) and Y-Z (right) projections indicate that SMCs did not remain
positioned on top of the EC monolayer. (bar: 10 µm)

97

3.3 Contractility measurements of IPAH PASMCs
Given the challenges in readily generating an arterial wall model, we performed a number
of characterizations of PASMCs isolated from the lungs of patients with IPAH using
more traditional tissue culture models. First, to determine whether these cells might be
contributing to the hypertensive state via increased contractility, we examined the levels
of myosin light chain (MLC) phosphorylation (Fig. 3.5). Comparison of donor cells from
one IPAH lung versus control cells revealed only a minor increase in ppMLC expression.
Treatment with several cytoskeletal tension inhibitors (Y27632: RhoA, ML-9: myosin
light chain kinase, blebbistatin: myosin II, NSC 23766: Rac1) led to a differential
response between the two cell populations when treated with ML-9. Treatment with
blebbistatin, however, did not lead to decreased ppMLC expression in either cell
population.
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Figure 3.5 ppMLC expression levels in IPAH PASMCs. (A) Quantification of
western blot for ppMLC in lysates from IPAH and control PASMCs. Lanes in B
are 1) DMSO, 2) Y27632, 3) ML-9, 4) blebbistatin, 5) NSC 23766, 6) Y27632 +
NSC 23766 in control cells, and 7) DMSO, 8) Y27632, 9) ML-9, 10) blebbistatin,
11) NSC 23766, 12) Y27632 + NSC 23766 in IPAH PASMCs isolated from lung
#8.

The lack of a decrease in phosphorylation levels of MLC upon treatment with
blebbistatin led us to pursue assays with direct functional read outs of contractility. We
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employed a collagen gel contractility assay to compare the ability of IPAH and control
SMCs to contract a free floating collagen gel (Fig. 3.5). IPAH PASMCs cultured for 4
days in 2.5 mg/ml collagen gels showed no clear trends in differences in contractility
versus control PASMCs. Only cells isolated form IPAH Lung 1 exhibited decreased
contractility. Cells from other donors exhibited contractility levels very similar to those
observed in control PASMCs.

Figure 3.6 IPAH SMC contractility in collagen gels. Percent contraction of
collagen gels containing IPAH and control PASMCs cultured for 4 days.

To better understand the contractile behavior of IPAH and control cells, we
employed microfabricated post-array detectors (mPADs) to directly measure the traction
forces exerted by individual cells (Fig. 3.7A) (Tan et al., 2003). Deflections measured
upon seeding control and IPAH PASMCs onto mPADs showed only a moderate increase
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in the IPAH cells (Fig. 3.7B). mPAD devices allowed us to make a variety of
measurements including force per post, force per cell, and cell area. Measurements of cell
area indicated that the IPAH SMCs spread to slightly larger areas. This increase in spread
area contributed slightly to the total force per cell exerted by these cells. When cells with
similar areas were compared, no differences in total traction force were observed. The
most significant difference in traction forces were observed in measurements of traction
force per post. These differences, however, were not statistically significant when
compared via a student’s t-test (p > 0.05).
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Figure 3.7 Measurements of traction forces generated by IPAH PASMCs. (A)
Representative images of control and IPAH PASMCs seeded onto mPADs. (red:
DiI, tops of PDMS posts, arrows: force vectors) (bar: 10 µm) (B) Measurements
of force exerted per post by control and IPAH PASMCs. (errors bars represent sd
in expts. 1, 2, and 3 and sem in pooled data, measurements of at least 20 cells of
each type were made in each experiment).
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3.4 Further characterization of IPAH PASMCs
Observations of the IPAH PASMCs in routine culture suggested that they may exhibit an
altered adhesive behavior. To test this hypothesis, we labeled control and IPAH SMCs
with CyQUANT dye and determined the relative numbers of cells that remained attached
to substrates coated with varying concentrations of fibronectin after 45 minutes. We
performed this adhesion assay with 3 control and 3 IPAH cell lines, which were newly
acquired. Results indicated that cells from all 6 cell lines were able to adhere in much
larger quantities when the fibronectin concentration was increased to at least 1 µg/ml Fig.
3.8). Differences between individual or pooled control and IPAH groups were not
significant. Minor variations to this tend were observed at individual time points but no
significant trends were observed overall.
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Figure 3.8 Adhesion of control and IPAH PASMCs to fibronectin-coated
substrates. Quantification of control and IPAH cells labeled with CyQUANT and
seeded onto polystyrene substrates coated with varying concentrations of
fibronectin (measurements represent average of three replicate wells per
condition).

Given that aberrant proliferation of vascular cells is a hallmark of pulmonary
hypertension, we decided to investigate the proliferative behavior of IPAH SMCs (Chin
& Rubin, 2008). First, we confirmed that both control and IPAH PASMCs grown to
confluence and treated with serum free medium ceased proliferating and remained viable
in culture. Once a successful synchronization protocol was established, we investigated
the effects of seeding density on proliferation in both control and IPAH cells. IPAH and
control cells both exhibited a biphasic response in proliferation rates when seeded at low,
medium or high densities (Fig. 3.9A). Proliferation reached a maximum at medium
104

density (some cell-cell contact but not yet confluent) and a minimum at low (little to no
cell-cell contacts) and high (near confluence) densities. In general, IPAH PASMCs were
found to proliferate at rates approximately twice as high as those in control cells. To
further investigate whether cell-cell contacts may be abnormal in IPAH cells, we assayed
the basal expression levels of N-cadherin. Western blots indicated that N-cadherin
expression in IPAH cells was significantly lower than in control cells. Additionally, we
found that IPAH and control PASMCs transduced via an adenoviral vector with a
dominant negative form of N-cadherin proliferated at similar rates. This result suggested
that proliferation in IPAH SMCs could be lowered to normal levels by knockdown of Ncadherin. More extensive studies of proliferative regulation in IPAH PASMCs are
described in section 3.5 below.
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Figure 3.9 Effects of cell density and N-cadherin expression on IPAH PASMC
proliferation (A) Both control and IPAH PASMCs exhibit a biphasic response in
proliferation to varying levels of cell density. Overall proliferation rates were
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approximately two-fold higher in IPAH cells (data represent at least 150 cells of
each type counted from a single experiment). (B) IPAH PASMCs expression
levels are approximately one-fourth lower than in control cells (data represents
one experiment) (C) Expression of dominant negative N cadherin significantly
lowered proliferation rates in both IPAH and control cells. Proliferation in IPAH
PASMCs expressing NΔ dropped to levels below those in control cells (data
represent average proliferation rates of at least 150 cells in each condition from a
single experiment).

To further characterize the phenotype of IPAH PASMCs, we performed
quantitative real-time PCR analysis for a panel of SMC differentiation markers. We
found that all SMC differentiation markers examined (smooth muscle actin α-2, calponin,
myocardin, SM22α and smoothelin) were downregulated in the IPAH PASMCs (Figure
3.10). Taken together, the proliferation and gene expression data suggest that the IPAH
PASMCs are likely to have undergone a switch from a differentiated to a less
differentiated, highly proliferative phenotype. Subsequent analysis of additional IPAH
donor cells, however, indicated that the observed trends were evident in only one IPAH
PASMC cell line.
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Figure 3.10 SMC marker expression levels of control versus IPAH PASMCs.
SMC marker expression levels were measured by qRT-PCR. Cells were G0
synchronized, replated at a density of 5,000 cells/cm2 prior to RNA isolation.
(data are expressed as ± SEM from at least 3 independent experiments. *, p <
0.05)

Previous studies have shown that decreased expression levels of the basement
membrane protein perlecan might contribute to SMC hyperplasia in vivo (Tran et al.,
2004). Immunofluorescent staining of IPAH PASMCs suggested that they might express
reduced levels of perlecan in culture (Fig. 3.11). While it is plausible that IPAH PASMCs
exhibit abnormal expression levels of ECM proteins in culture, these findings remain to
be confirmed by western blot analysis and in a variety of donor cell lines.
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Figure 3.11 Perlecan deposition patterns in IPAH PASMC cultures. Cells were
plated at a density of 5,000 cells/cm2 and fixed 24 hours later. Staining patterns
suggest that perlecan deposition by IPAH PASMCs may be lower than those in
control cells. (bars: 25 µm)

3.5 Proliferative regulation by adhesion and Rho GTPases is altered in
IPAH PASMCs
3.5.1 Proliferation in IPAH SMCs is Rho-dependent
To test whether SMCs isolated from lungs of patients with IPAH exhibited a
hyperproliferative phenotype in vitro, we cultured isolated PASMCs and measured their
rate of S phase entry via a bromodeoxyuridine incorporation assay. PASMCs isolated
from diseased lungs of multiple donors showed a significant increase in proliferation over
control cells isolated from individuals without PAH (Fig. 3.12A). These results suggest
that SMCs from patients IPAH retain their in vivo hyperproliferative phenotype when
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isolated. Additionally, routine observation of control and IPAH SMCs in culture
indicated the possibility of differences in adhesion between the IPAH and control cells.
Specifically, the IPAH SMCs appeared to attach and spread more quickly than control
cells (data not shown). Because the small GTPases RhoA and Rac 1 play known roles in
cytoskeletal reorganization during cell spreading and in proliferative control, we
investigated whether the RhoA or Rac 1 signaling pathways were involved in the
proliferative control of IPAH PASMCs. After synchronizing control and IPAH PASMCs
in G0 , we replated the cells onto fibronectin in the presence of either the ROCK inhibitor
Y-27632 or NSC-23766, to block Rac 1 signaling. We found that the hyperproliferation
exhibited by IPAH PASMCs was reduced to levels comparable to those of the control
cells via treatment with Y-27362. Control PASMCs were significantly less affected by Y27632 treatment, but were particularly sensitive to NSC-23766 treatment (Fig. 3.12B).
These data suggest that PASMCs of patients with IPAH may undergo a Rac-to-Rho
proliferative control switch.
To further substantiate whether RhoA signaling might be higher in IPAH cells,
we compared RhoA activity levels in PASMCs from a single diseased lung and a control
lung. We found that the IPAH PASMCs have a greater than 2-fold higher RhoA activity
as compared to the control cells (Fig. 3.12C). Taken together, these results suggest that
RhoA signaling is altered in IPAH and that this may underlie the aberrant proliferation of
IPAH PASMCs.
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Figure 3.12 Proliferation rates of control and IPAH PASMCs in culture. (A)
Baseline proliferation of isolated control and IPAH SMCs as measured by BrdU
incorporation. *, p < 0.05. (B) Proliferation of control and IPAH SMCs after
treatment with the RhoA inhibitor Y-27632 or the Rac inhibitor NSC-23766. Data
represent pooled results from all control or IPAH donor cells. *, p < 0.05 for
comparison of untreated control PASMC vs. IPAH PASMC. #, p < 0.05 for
comparison of untreated control PASMC vs. drug-treated control PASMC. ^, p <
0.05 for comparison of untreated IPAH PASMC vs. NSC-23766-treated IPAH
PASMC. (C) RhoA activity levels measured in a single control and IPAH donor
cell population. *, p < 0.05. All data (panels A, B, and C) are expressed as ± SEM
from at least 3 independent experiments.

3.5.2 Adhesion signaling is altered in IPAH PASMCs
Focal adhesions are mechanical and biochemical linkages between the cell and its
extracellular environment. Because focal adhesion size is known to be regulated by RhoA
signaling (Chrzanowska-Wodnicka & Burridge, 1996), we sought to examine whether
focal adhesion architecture or the expression levels of focal adhesion proteins might be
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altered in IPAH PASMCs. We first investigated whether differences in the expression of
vinculin, a key focal adhesion protein, existed in IPAH versus control cells. Indeed, we
observed that IPAH PASMCs exhibited significantly higher vinculin expression than the
control PASMCs (Fig. 3.13A). To visualize focal adhesion size and architecture, we
performed vinculin immunostaining and found that focal adhesions appeared longer in
IPAH cells versus controls (Fig. 3.13B). Quantification of focal adhesion length revealed
that adhesions in cells from patients with IPAH were almost 50% larger than those in
control PASMCs (Fig. 3.13C).
To investigate whether altered focal adhesion structure might also give rise to
differences focal adhesion signaling, we measured the phosphorylation status of focal
adhesion kinase (FAK), a key signaling molecule within focal adhesions. We found that
IPAH SMCs expressed higher levels of FAK phosphorylated at Y397
(autophosphorylated FAK) than control cells (Fig. 3.13D). The aberrant focal adhesion
size and signaling may contribute to the observed proliferation differences.
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Figure 3.13 Focal adhesion size, structure, and FAK phosphorylation status in
IPAH PASMCs. (A) Representative blots and quantification of vinculin
expression in control and IPAH PASMCs. Quantification represents pooled data
from all control and IPAH donors. *, p < 0.05. (B) Representative
immunostaining for vinculin in control and IPAH PASMCs. Scale bar: 20 mm.
(C) Quantification of average focal adhesion length in control and IPAH
PASMCs. *, p < 0.01. (D) Representative blots and quantification of total and
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phospho-397 FAK in control and IPAH PASMCs. Data are expressed as ± SEM
for panels A-C and ± SD for panel D.

3.5.3 High proliferation in IPAH PASMCs is mediated by altered adhesion signaling
Cell adhesion to the extracellular matrix is a known regulator of cell growth and involves
the physical spreading of cells against an underlying substrate (C. Chen et al., 1997;
Raines, 2000). As expected, control PASMCs exhibited a nearly complete inhibition of
proliferation when cultured on micropatterned substrates in which the geometry of the
printed patterns limit the cell’s ability to fully spread (Fig. 3.14A). Surprisingly, this
adhesion-mediated growth control appears to be lost in IPAH PASMCs, which maintain
their high proliferation rates even in a context of limited cell spreading (Fig. 3.14A).
Because we have demonstrated that adhesion signaling through FAK is high in IPAH
PASMC and that these cells exhibit altered adhesion-mediated growth control, we next
investigated whether pharmacological inhibition of FAK would restore normal adhesionmediated growth control in IPAH PASMC. We plated G0-synchronized IPAH PASMCs
or control PASMCs onto micropatterned islands of fibronectin and treated with the FAK
inhibitor PF-573,288. Blocking FAK signaling restored normal adhesion-mediated
growth control mechanisms in the IPAH PASMCs (Fig. 3.14B). Together, these data
suggest that IPAH PASMCs exhibit altered adhesion signaling, which appears to drive
their hyperproliferation in culture.
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Figure 3.14 Adhesion-mediated proliferative control in IPAH PASMCs. (A)
Proliferation of control and IPAH PASMCs on unpatterned (spread) and patterned
(unspread) fibronectin-coated substrates. (B) Proliferation of control and IPAH
PASMCs treated with PF-573,228 and seeded onto patterned fibronectin-coated
substrates. All data are expressed as ± SEM. *, p < 0.05 for comparison of control
vs. IPAH PASMC under spread conditions. #, p < 0.05 for comparison of IPAH
PASMC under spread vs. unspread conditions.

3.6 Materials and Methods
Cell Isolation
Lungs from IPAH patients were obtained through the Pulmonary Hypertension
Breakthrough Initiative consortium. The lungs were grossly dissected by following the
main pulmonary artery and subsequent branches until reaching the terminal vessels. The
dissected arteries were then divided into three categories based on vessel diameter and
the adventitia was removed by further dissection. For our studies, vessels with a diameter
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of 1–5 mm were used. After isolation they were sectioned into approximately 30 mm
long segments and placed into 100 mm tissue culture dishes with 10 mL SmGM-2
Smooth Muscle Growth Medium (Lonza). After two weeks, an additional 5 mL of
growth medium was added, and a 50% change of growth medium was performed after a
total of three weeks in culture. At this time, any remaining tissue was removed from the
culture dish, and the remaining PASMCs were cultured under standard conditions as
described below. Control PASMC were isolated from patients without pulmonary
arterial hypertension using the same procedure.

Cell culture and reagents
PASMCs were cultured in Smooth Muscle Growth Medium-2 (Lonza) and were
maintained at 37°C in a humidified CO2 incubator. Y27632 and NSC23766 were
purchased from EMD Biosciences. PF-573,228 was purchased from Tocris. All
experiments were performed using cells at passage 8 or earlier.

Proliferation Assays
Control or IPAH diseased PASMC were G0 synchronized by serum starvation for 24
hours. Cells were then trypsinized and replated in the presence of BrdU (GE Healthcare).
Cells were fixed at 24 hours and stained for BrdU incorporation using a monoclonal
antibody directed against BrdU (GE Healthcare) followed by incubation with an
AlexaFluor-594-conjugated anti- mouse secondary antibody (Invitrogen). Cells were
counterstained with Hoechst 33342 (Invitrogen). For inhibitor studies, cells were treated
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with 25µM Y27632, 50µM NSC23766, or 5µM PF-573,228 at the time of plating after
synchronization.

Quantitative Real-Time PCR Analysis of Smooth Muscle Cell Markers
Prior to lysis, cells were grown to confluence, cultured in the absence of serum for 24 h,
and replated at a density of 5,000 cells/cm2. The cells were then lysed and RNA was
isolated using the RNeasy Micro Kit (Qiagen). 0.5 µg of RNA from each sample was
spotted in triplicates into a 96-well PCR plate (ISC BioExpress) along with nuclease-free
water (Ambion) and oligo(dT) primer (Promega). The plate was heated to 70 oC for 2
min, after which a master RT-PCR mix containing 5x first strand buffer (Invitrogen),
dNTP mix (Promega), RNasin RNase inhibitor (Promega) and M-MLV reverse
transcriptase (Promega) was added. The RT reaction was run using an Eppendorf
Mastercycler Gradient thermal cycler as follows: 42 oC for 1.5 h, 94 oC for 5 min, hold at
4 oC. 80 µL water was added to the samples containing cDNA, and they were stored at 20 oC. Quantitative real-time PCR was performed in triplicate using TaqMan probes
specific for ACTA2, CNN1, MYOCD, SM22, SMTN and GAPDH (Applied Biosystems)
with the FAM dye label. The real-time PCR reaction was run using an Applied
Biosystems 7300 Real- Time PCR System using standard conditions: 2 min at 45 oC, 30
sec at 95 oC, and 40 cycles of 2 sec at 95 oC denaturation and 60 oC annealing/extension.
Results were quantified using the comparative CT method with GAPDH used as the
reference amplification. Data for each marker were normalized to the control PASMC
sample.
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Immunocytochemistry, image analysis, and quantitative analysis of focal adhesions
Quantitative analysis of focal adhesions was performed as previously described (Pirone et
al., 2006). Briefly, cells were incubated for 1 min with ice-cold cytoskeleton buffer (50
mM NaCl, 150 mM sucrose, 3 mM MgCl2, 1µg/mL of the following protease inhibitors:
aprotinin, leupeptin, pepstatin, and 2 mM PMSF), followed by 1 min in ice-cold
cytoskeleton buffer supplemented with 0.5% Triton-X 100. Detergent extracted cells
were fixed in 4% formaldehyde in PBS, washed, and incubated with the hVin-1 primary
antibody against vinculin (Sigma-Aldrich). Vinculin staining was visualized by
incubation with an AlexaFluor-594-conjugated secondary antibody (Invitrogen).
Quantitative microscopy of focal adhesions was performed using a SPOT camera
(Diagnostic Instruments) attached to an inverted microscope (Zeiss, Axiovert 40 CFL)
using a 63X oil immersion objective. Images were obtained and processed using SPOT
software (Diagnostic Instruments) to measure the length of individual focal adhesions.
Approximately 10 cells were analyzed per experimental condition.

RhoA activity assays
RhoA activity was quantified using an absorbance based G-LISA RhoA Activation Assay
(Cytoskeleton) according to the manufacturer’s instructions. Briefly, IPAH or normal
control PASMCs were grown to confluence and serum starved for 24 hours. The cells
were then plated into fibronectin coated (25 µg/mL) dishes at a density of 7,000 cells/cm2
and lysed with the provided lysis buffer after 4 hours. Total protein concentration was
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measured using the supplied reagents and each sample was added to duplicate wells of
the provided 96-well plate. Following the manufacturer’s protocol, antigen presenting
buffer, primary antibody solution, secondary antibody solution and HRP detection
solution were sequentially added to the wells. The signal was read by measuring
absorbance at 490 nm using a multifunction microplate reader (TECAN GENios,
TECAN).

Western Blots
Cells were washed in TBS and lysed in cold RIPA buffer. Proteins were separated by
denaturing SDS-PAGE, electroblotted onto a PVDF membrane (Bio-Rad Laboratories),
blocked with 5% milk in TBS, immunoblotted with specific primary antibodies, and
detected using horseradish peroxidase–conjugated secondary antibodies (Jackson
ImmunoResearch Laboratories) and SuperSignal West Dura (Pierce Chemical Co.) as a
chemiluminescent substrate. Densitometric analysis was performed using a VersaDoc
imaging system with QuantityOne software (Bio-Rad Laboratories).

Micropatterned Substrates
To generate stamps for microcontact printing of proteins, a prepolymer of
poly(dimethylsiloxane) (PDMS; Sylgard 184; Dow Corning) was poured over a
photolithographically generated master, as previously described (C. Chen et al., 1997).
Stamps were immersed for 1 h in 50 µg/ml fibronectin, washed three times in water, and
blown dry under nitrogen. Coated stamps were placed in conformal contact with a
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surface-oxidized PDMS- coated glass coverslips. Stamped coverslips were immersed in
0.2% Pluronic F127 (Sigma-Aldrich) in PBS for 1 h and washed.

3.7 Conclusions
Organotypic models provide an important intermediate platform between traditional
tissue culture models and in vivo studies for investigations into disease mechanisms in a
physiologically relevant context. In previous studies, models of the arterial wall have
been proposed that utilize sequentially seeded layers of SMCs and ECs to form a bilayer
mimicking the intimal and medial compartments of arteries (Niwa et al., 2007; Ziegler et
al., 1995). In the work described here, we have attempted to replicate a version of this
model using bPAECs and bPASMCs with the eventual goal of employing ECs and SMCs
derived from patients with IPAH. However, bPAECs seeded onto monolayers of
bPASMCs treated with ascorbic acid failed to spread and form monolayers. As an
alternative approach, we sought to generate layers of SMCs cultured atop confluent
layers of ECs. However, failure to also generate this ‘inverse’ arterial wall model led us
to abandon these approaches and focus on studying mechanisms regulating the
proliferation of IPAH PASMCs using more traditional tissue culture models.
IPAH is characterized by an increase in SMC proliferation and subsequent
occlusion of the luminal space. While we have a basic understanding of the
pathophysiology of IPAH as it relates to vascular architecture, the underlying molecular
etiology of the proliferative-driven thickening of the tunica media remains unclear. In the
work presented here, we have demonstrated that the regulation of proliferation via Rho
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GTPase activity and adhesion signaling pathways are dysfunctional in vascular SMCs
isolated from patients with advanced IPAH.
Overall, our data presented here suggest the presence of a defect in the
proliferative regulation mechanisms of SMCs obtained from patients with IPAH. These
IPAH cells display a higher than normal expression of RhoA, increased focal adhesion
size, and aberrant focal adhesion signaling, all of which are key in properly modulating
proliferation. This lack of proliferative regulation via focal adhesions and cell spreading
is reminiscent of an SMC phenotype found in neointimal lesions of IPAH patients (Chin
& Rubin, 2008). Taken together, these findings suggest that the underlying etiology of
IPAH is likely to have a mechanochemical basis.
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CHAPTER 4: Discussion and Future Directions

4.1 Discussion of patterned endothelial cell cords for vascularizing
engineered tissues
4.1.1. In vitro generation of endothelial cell cords
In the work described in Chapter 2, we have developed a novel strategy for generating
functional capillaries with spatially controlled geometry in vivo. Our technique relies on
the implantation of patterned endothelial cell cords into mice. The cords are formed using
microfabricated PDMS templates to spatially arrange endothelial cells within collagen
gels. We observed that HUVEC and 10T1/2 cells organized into cords through a
contractility dependent process and have previously shown that they exhibit proper cellcell junction formation (Raghavan, Nelson, Baranski, Lim, & Chen, 2010a).
Most in vitro approaches for generating constructs for the study of vascular
biology have focused on creating endothelialized tubes (Chrobak et al., 2006; Miller et
al., 2012). While these strategies are capable of generating increasingly complex
architectures, their application has been limited to the creation of large diameter tubules.
Other studies have demonstrated that endothelial cells seeded onto thin (10 µm) lines of
patterned matrix also leads to the formation of cords (Dike et al., 1999). While this
approach is capable of generating geometrically patterned cords, here we demonstrate the
additional ability to alter cord diameter and, most importantly, the ability to embed the
cords into implantable tissue constructs for further study in vivo. Our approach for
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patterning cells into cords is capable of generating complex branched networks and
geometries that mimic native vasculature within engineered tissues. In addition, because
the cords in our system are formed in a separate step from their embedding into a
surrounding material, they can be readily used to combine patterned vasculature with
parenchymal or other cells. As an example, we demonstrate that aggregates of
hepatocytes embedded into the matrix surrounding patterned cords exhibit improved
function due to increased vascular access.
In the studies described in Chapter 2, EC cords were removed into fibrin, a natural
ECM material that has been used extensively in angiogenic applications and one whose
proangiogenic properties of have been well documented (X. Chen et al., 2009; Ghajar,
Blevins, Hughes, George, & Putnam, 2006; Hall et al., 2001; Lesman et al., 2011). To
study the effects of ECM properties on vascularization of engineered tissue constructs,
one might envision embedding cords within ECMs such as PEG hydrogels that allow for
independently varying material properties (Miller et al., 2010; Moon et al., 2011). Other
natural ECMs such as Matrigel have been shown to elicit a strong angiogenic response in
vivo (Passaniti et al., 1992). While our work has been limited to the use of fibrin as the
proangiogenic scaffold for embedding cords, one could envision studies that utilize a
variety of materials with different properties to gain better insights into the vascular
response.
Our in vitro characterizations revealed that cords form via the cells’ compaction
of surrounding ECM using a contractility dependent process and that cells are distributed
randomly throughout the fully formed cords. Over three decades ago, studies first showed
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that fibroblasts embedded within a collagen gel progressively contract and reduce the
diameter of the gel (E. Bell, Ivarsson, & Merrill, 1979). More recently, it has been shown
that endothelial cells also exhibit similar contractile behavior in collagen gels (Vernon &
Sage, 1996). Although the cords described here are geometrically different than the discs
typically used in these contractility studies, it is likely that the contraction we observe in
cords is driven by the same mechanisms. In their study Sage and colleagues observed that
endothelial cells contracted collagen gels similarly to dermal fibroblasts. Although the
traction forces generated by C3H10T1/2 cells have never been assayed directly, it is
likely that they exhibit similar contractile forces to that of other cells of mesenchymal
origin such as fibroblasts. Given comparable levels of contraction to that of HUVECs and
the relatively low abundance of 10T1/2s in our cords, it is not surprising that their
absence has no measurable effect on the rate or degree of cord formation. To precisely
tease out the relative contributions of each cell type, one might envision experiments
involving the direct measurements of traction forces exhibited by each cell type as well as
measuring the contraction rates of gels formed with varying proportions of the two cell
types. However, the formation of cell-cell contacts and juxtaposition of neighboring cells
rather than contractility likely contribute most to the vascularization process in vivo
(discussed below).
4.1.2 The vascularization response to implanted endothelial cell cords
Implantation of tissue constructs containing cords of endothelial cells led to the formation
of functional capillaries in vivo. We observed that the capillary walls were comprised of
implanted endothelial cells and became perfused with blood within 3 days PI. Previous
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studies of engineered vasculature have shown that implanted endothelial cells contribute
directly to the formation of vessels and persist for up to one year in vivo (X. Chen et al.,
2010; Koike et al., 2004). Our findings that viable cells within cords are required for the
vascularization response suggest that similar mechanisms of cells organizing into
lumenized vessels take place within the vascularization strategy described here.
While our analyses here have been limited to post-sacrifice histology and
imaging, one might envision the use of longitudinal intravital imaging techniques to
directly observe the cellular dynamics within implanted cords (Au, Daheron, Duda,
Cohen, Tyrrell, et al., 2008a; White et al., 2012). Histological studies of implanted EC
cords indicate that cells of human origin persist within the capillaries for at least 28 days.
We also observe, however, that these vessels remodel significantly upon formation,
becoming smaller, invested by pericytes, and more numerous. While no notable
differences exist between capillaries within cords and the host vasculature, the formation
process of the engineered is likely unique. Interestingly, events in vascularization upon
implantation of EC cords resemble early processes in both vasculogenesis and
angiogenesis. In vasculogenesis, aggregates of angioblasts, or endothelial precursor cells,
organize around blood islands to form nascent vessels (Risau & Flamme, 1995). In
angiogenesis, prior to forming a lumen sprouting endothelial cells migrate collectively as
a ‘cord’ (Adams & Alitalo, 2007). Patterned cords of endothelial cells likely become
vascularized utilizing a combination of mechanisms that underlie these two physiological
processes. To shed light on some of the underlying mechanisms that drive the
vascularization process, one might envision adapting our vascularization strategy for use
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with longitudinal intravital imaging techniques. Questions particularly worthy of
investigation using such a system might be: 1) how do implanted ECs sort and migrate to
form lumenized vessels? 2) what is the fate of implanted ECs that do not become
incorporated into the walls of capillaries? 3) do implanted 10T1/2 cells contribute to the
pericyte population observed in mature capillaries? While our data demonstrate the
successful formation of spatially controlled capillary networks in vivo, further studies
such as those described above will undoubtedly herald manipulations that allow an
additional level of control over the vascularization process.
4.1.3 Role of cell type in the vascularization response upon implantation of
endothelial cell cords
A variety of cell types have successfully been used in various strategies for engineering
microvasculature (Au, Daheron, Duda, Cohen, Tyrrell, et al., 2008a; Au, Tam,
Fukumura, & Jain, 2008b; X. Chen et al., 2010; Ghajar et al., 2006; Melero-Martin et al.,
2008). Findings by George and colleagues indicate that cell networks formed prior to
implantation lead to a more robust vascularization response in vivo (X. Chen et al., 2009).
Here, we confirmed that a 1:50 combination of C3H10T1/2s:HUVECs exhibits extensive
networking behavior when embedded within collagen gels in vitro. Additionally,
previous studies have demonstrated that 10T1/2s are capable of contributing to the
vascularization process by differentiating into smooth muscle cells or pericytes
(Hirschi et al., 1998). Based on these findings, the majority of studies described here
were conducted using a combination of 1:50 10T1/2s and HUVECs. Our data suggest
that nearly all capillaries formed in the implanted cords exhibited the presence of α126

SMA-positive cells immediately adjacent to the vessel walls. While the HUVECs could
be readily identified using immunohistochemical techniques due to their human origin,
we were unable to immunostain the murine-derived 10T1/2s. A study utilizing labeled
10T1/2 cells (e.g. with GFP) is needed to definitively elucidate their contribution to the
vascularization process. It could be postulated that alternative mechanisms could be
responsible for recruiting α-SMA-positive of host origin to the forming vessels. Studies
have shown that circulating perivascular progenitor cells can contribute to tumor
angiogenesis (Mancuso et al., 2011). While unlikely, sources of pericytes such as these
cannot be ruled out until more detailed studies are conducted. Despite lacking knowledge
on the exact role of 10T1/2s in implanted EC cords, our data and other studies suggest
that they play a direct role in driving the maturation of newly formed capillaries.
Previous studies have shown that endothelial cells of various origins exhibit
different levels of angiogenic potential in vivo (Barclay et al., 2012). While the HUVECs
employed in our studies have a verified endothelial phenotype including the expression of
CD31 and von Willebrand factor, their capability to contribute to angiogenesis was not
directly tested. Vascularization strategies employed by others have utilized a variety of
cell types including human adult and cord blood derived endothelial progenitor cells and
human embryonic endothelial cells (Levenberg et al., 2005; Melero-Martin et al., 2008).
Future studies should focus on the ability of these and other cell types to contribute to the
vascularization process in implanted EC cords.
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4.1.4 Role of growth factor signaling in the vascularization response upon
implantation of endothelial cell cords
Previous studies have shown that production of growth factors such as VEGF by
pericytes is associated with endothelial cell survival (Darland et al., 2003). Additionally,
PDGF produced by endothelial cells works to recruit and maintain pericytes in a
differentiated state (Hirschi et al., 1998). Such VEGF/VEGFR and PDGF/PDGFR
paracrine loops between HUVECs and 10T1/2 cells are likely at the heart of growth
factor signaling within EC cords. While not directly measured in our studies, previous of
angiogenic mechanisms have demonstrated that HUVECs respond to canonical
proangiogenic growth factors such as VEGF (Angulo et al., 2011). Additionally, it has
been shown that HUVECs modulate the proliferation and differentiation of 10T1/2 via
PDGF when cultured together (Hirschi, Rohovsky, Beck, Smith, & D'Amore, 1999).
While these signaling pathways help to regulate HUVEC and 10T1/2 angiogenic
behavior within cords in vitro, they are subject to an additional milieu of growth factors
upon implantation. Differentiatied 10T1/2s are known to produce VEGF and maintain
endothelial cell survival (Darland et al., 2003). Likely, 10T1/2s embedded within cords
signal not only to adjacent HUVECs but also to the surrounding host tissue. Indeed, our
data suggest that angiogenic activity leads to capillary formation between adjacent cords
(Fig. 2.25), a phenomenon that is likely driven by secretion of growth factors from
adjacent cords.
Host tissue is undoubtedly affected by growth factor signaling from implanted
cords. Likely, factors including VEGF and PDGF stimulate angiogenic sprouting from
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otherwise quiescent host vessels and help to recruit mural cells to forming capillaries,
respectively. Indeed, it has been shown that implanted endothelial cells elicit a wound
healing response in host tissue that is regulated by growth factors including VEGF and
PDGF among others (Soejima, Negishi, Nozaki, & Sasaki, 1998). While our histological
analyses do not suggest that a host angiogenic response reaches the center of implanted
constructs, we do observe vessels of host origin near the periphery. Likely, this
angiogenic response from host vessels is driven in large part by secreted growth factors.
Localization of growth factor signaling to the periphery of implanted constructs is further
supported by evidence that secreted VEGF is largely cell- or matrix-bound, effectively
limiting its ability to signal over large distances (Darland et al., 2003).
In vivo, growth factors are secreted into the surrounding matrix and form complex
spatiotemporal gradients within tissues, making their detection and characterization
particularly challenging (Guo et al., 2012). Additional study into the role of growth factor
signaling in the vascularization response upon implantation of EC cords could be
undertaken by loss- or gain-of-function studies and pharmacological inhibition. Namely
HUVECs or 10T1/2s lacking VEGF, PDGF, or their receptors might be used to generate
cords. Subsequent implantation and histological analyses would shed light on the
requirements of these angiogenic factors in the vascularization response. Specifically, it
might be hypothesized that VEGF production by the implanted cells is required to elicit a
proper angiogenic response from the surrounding host tissue. Thus, it would be
interesting to investigate whether implantation of VEGF-null cells would still result in
proper anastomosis and connection with the host vasculature. Additionally, one might
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envision the use of pharmacological inhibitors of growth factor receptors to probe their
roles in different stages of the vascularization response. For example, PDGF inhibitors
could be introduced at day 5 post-implantation to determine whether it is required for
capillary maturation. Lastly, materials with controlled-release properties might be
employed to gain a degree of control over the delivery of the growth factors (Laham et
al., 1999; Lin & Anseth, 2008). Use of such materials, however, would first require a
thorough characterization of their capabilities in driving vascularization in tissue
constructs containing EC cords.
4.1.5 Role of the extracellular matrix in the vascularization response upon
implantation of endothelial cell cords
To date, a variety of natural and synthetic matrices have been used for generating
vasculature in vivo (Lovett et al., 2009; Moon et al., 2011; Peters et al., 2002; Phelps &
García, 2010). In the system described here, the combination of type I collagen and fibrin
provides a permissive environment for vessel formation that consists of natural ECM
materials that can be remodeled by cells over time. Both fibrin and collagen have been
extensively used in tissue-engineered vascularization strategies and the proangiogenic
activity of fibrin is well documented (X. Chen et al., 2009; Hall et al., 2001; Lesman et
al., 2011; Oh, Lu, Kawazoe, & Chen, 2011; A. Y. Wang et al., 2008). The regulation of
angiogenesis by ECM is largely manifested through its degradation by matrix
metalloproteinases (Ghajar, George, & Putnam, 2008b). Here, we observed signs of fibrin
degradation as early as 7 days PI. Likely, this degradation is a required and permissive
cue for the sprout formation that we observed between capillaries in adjacent cords and at
130

the edges of implanted constructs. While these findings suggest that cells within cords
actively remodel the fibrin matrix upon implantation, it is not clear whether MMP
activity is required for the vascularization process. Indeed, because the ends of EC cords
are often exposed near the edges of the encapsulating fibrin gel, matrix degradation may
not be required for the host vasculature to enter into contact with the implanted cords.
Given the rapid rate of vascularization that we observed, it is plausible that MMPs may
only become upregulated over time as newly formed vessels begin to remodel.
Interestingly, we observed no signs of collagen degradation within the cords. Studies
have shown that specific MMPs, namely MT1-MMP, play a pivotal role in angiogenic
processes both in vitro and in vivo (Collen et al., 2003). Given that various MMPs act
selectively on the various ECM components, it would be especially interesting to
examine their secretion patterns within tissue constructs containing EC cords. Ultimately,
more elaborate studies employing MMP-resistant synthetic materials or genetic
manipulations of MMP expression within implanted cells could be used to gain further
insights into their role in the vascularization response described here.
When cultured cells are placed in a three dimensional environment such as within
a gel of ECM, their proliferation rates typically decrease significantly (Cukierman,
Pankov, & Yamada, 2002; Cukierman, Pankov, Stevens, & Yamada, 2001). In addition,
quiescent endothelial cells, whether in a monolayer on a tissue culture dish or in patent
vessel wall, exhibit very low rates of proliferation (S. M. Schwartz & Benditt, 1977).
These trends suggest that cells within the EC cords used in our studies also proliferate at
relatively low levels upon implantation. Accordingly, histological analysis did not reveal
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cell numbers within cords that appeared to be dramatically higher than those originally
implanted. This observation, however, is strictly qualitative and the question of
proliferation has not yet been fully explored within our system. Immunostaining for
proteins involved in cell cycle progression such as Ki-67 could be used a simple for
increased proliferation in the implanted cells.
4.1.6 Role of cell-cell contacts in the vascularization response upon implantation of
endothelial cell cords
We have demonstrated that implanted cords of ECs become rapidly perfused with host
blood upon implantation and form mature capillaries after just 7 days. While our results
show that these capillaries are comprised of juxtaposed endothelial cells, the precise role
of cell-cell contacts during capillary formation remains to be fully explored. Endothelial
cell-cell contacts are known to play a vital role in angiogenesis and vessel homeostasis
(Adams & Alitalo, 2007; Nguyen & D'Amore, 2001). In the context of engineered
vasculature, previous studies have shown that increasing the amount of cell-cell contact
between endothelial cells by ‘preculturing’ them for one week prior to implantation leads
to enhanced vascularization in vivo (X. Chen et al., 2009). These studies led us to
hypothesize that increased cell-cell contacts between ECs patterned into cords would
allow them to rapidly form patent vessels while maintaining the geometry of the cords. In
a previous study, we have shown that extensive CD31 cell-cell junctions form between
adjacent ECs within cords (Raghavan, Nelson, Baranski, Lim, & Chen, 2010a). It is
likely that the densely packed arrangement of HUVECs within cords allows them to form
numerous other types of cell-cell contacts including adherens and gap junctions.
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Formation of such contacts might allow cells within cords to act as a collective unit,
much like an angiogenic sprout, and quickly form patent vessels upon the introduction of
blood. While we have already shown that cords contain CD31 cell-cell junctions, the
presence of adherens and gap junctions could be confirmed via immunostaining for their
components including VE-cadherin and connexin 43, respectively. Such characterization
would pave the way for subsequent loss-of-function studies that might be used to directly
test the requirements for the presence of established cell-cell junctions during capillary
formation. Viral delivery of dominant negative mutants of VE-cadherin, N-cadherin (for
interfering with EC-10T1/2 interactions) or connexin 43 prior to cord formation could be
utilized for this purpose. Because cord formation appears to be driven by cytoskeletal
contractility, it is not likely that knockout of these proteins would interfere with this
process in vitro. Indeed, one might hypothesize that the relatively high cell density even
in uncontracted cords might be sufficient for extensive cell-cell contacts to rapidly form.
Consequently, the contraction phase of cord formation might not be required for the
vascularization response that follows their implantation.
Further histological studies such as those described in Chapter 2 will provide
insights into whether mature cell-cell junctions within cords are required for their ability
to drive capillary formation in vivo. Quantifiable outputs of these studies should include
the rate of vascularization (time required until evidence of blood, lumenized vessels),
vessel patency/leakiness, and long-term vessel stability. Implantation of heterologous
cells or tissues such as EC cords requires the use of immunodeficient host animals. This
requirement combined with lethal defects in animals whose cells are unable to form
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proper adherens or gap junctions limits loss of function studies to the realm of
manipulations of the implanted materials (Carmeliet et al., 1996; Radice et al., 1997;
Reaume et al., 1995). Additional insights into the role of cell-cell contacts in driving the
vascularization response could be achieved via gain of function experiments.
Specifically, one might test whether overexpression of junctional proteins could be used
to speed up or otherwise alter the vascularization response. If such manipulations were to
speed up vascularization, a particularly interesting follow-up experiment would be to
transiently overexpress the implicated junctional proteins. In such a model, one might
hypothesize while initially higher expression levels help to drive a rapid and robust
vascularization response that quickly produces patent vessels, the eventual return of the
expression levels to baseline might be necessary to ensure proper vessel function over the
long term. Overall, given the importance of cell-cell contacts in angiongenesis and
homeostasis in quiescent vessels, it is likely that they play a significant role in the
mechanisms underlying vascularization in our system.
4.1.7 Anastomosis with the host vasculature
Studies by George and colleagues have suggested that engineered capillary networks can
anastomose with host vasculature within 1 day of implantation (X. Chen et al., 2010).
Here, we have observed that implanted EC cords become perfused with blood within 3
days of implantation. Venous introduction of fluorescent dextran further confirmed that
capillaries within the cords are perfused with host blood after 2 weeks. The underlying
mechanisms of host-graft anastomosis in our system have not been fully elucidated,
however. Findings by Jain and colleagues have suggested a ‘wrapping-and-tapping’
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mechanism of anastomosis in engineered tissues (Cheng et al., 2011). Here, injections of
lectins specific for mouse or human endothelium have suggested that some cells of
mouse origin are present within the vessel walls near the edges of implanted constructs.
These data suggest that an angiogenic response from the host tissue is elicited, causing
typically quiescent host vessels to sprout and eventually connect with capillaries forming
within the implanted cords. Presence of solely this mechanism, however, seems unlikely
and would contradict the findings by Jain and colleagues. While not yet directly
observed, we predict that a ‘wrapping-and-tapping’ mechanism of anastomosis might
also play a role in the vascularization response described here.
Over the last several years, advanced methods for longitudinal intravital imaging
of angiogenic processes in rodents have been developed (Koike et al., 2004; White et al.,
2012). These imaging methodologies must now be adapted for use with the
vascularization strategy described here in order to better understand the mechanisms that
underlie host-graft anastomosis. Correctly predicting and imaging areas where
anastomosis might occur remains difficult in current vascularization approaches.
Interestingly, employing longitudinal intravital imaging techniques in conjunction with
our vascularization strategy might not only provide insights into mechanisms of
anastomosis within our system, but also enable investigators to more readily observe
anastomotic events. We have recently been able to elicit a vascularization response in
tissue constructs implanted subcutaneously by utilizing a mesh backing material. These
results suggest that monitoring of cellular dynamics and subsequent anastomosis within
an implanted window chamber is feasible.
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In addition to the canonical interactions between tip cells in anastomosing
angiogenic sprouts, research has recently shown that macrophages also play a role in
guiding the sprouting tips (Fantin et al., 2010). The studies described here were
performed in athymic mice, which, despite decreased immune function, possess the
ability to recruit macrophages to sites of injury. It is plausible that these cells might be
directly involved in the anastomosis of EC cords with host circulation. Experiments
including longitudinal in situ imaging described above and immunostaining for host
macrophages would shed additional light on this hypotheses.
4.1.8 Patterning of vasculature via implantation of endothelial cell cords
Spatial patterning of vessel architecture is necessary for the design of complex functional
vasculatures in engineered tissues (Vacanti, 2012). Previous studies have utilized
physical constraints such as PDMS templates or patterns of ECM-bound VEGF to guide
the host angiogenic response (Oh et al., 2011; Zheng et al., 2011). Additionally, general
approaches for vascularizing engineered tissues are limited to prevascularization of
constructs via self assembly of randomly distributed cells into rudimentary capillary
networks (X. Chen et al., 2009; Koffler et al., 2011; Koike et al., 2004; Melero-Martin et
al., 2008).
Here, via implantation of patterned EC cords, we have demonstrated one of the first
strategies for directly patterning capillaries in vivo. The geometry of the vasculature is
determined by directly patterning EC cords using a PDMS template that can be fabricted
to take a variety of shapes. Perfusion of the vasculature with fluorescent dextran showed
that spatial organization is preserved following implantation of either parallel arrays or Y
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shaped networks of cords. We hypothesize that in vivo, the shape of the resulting
capillary network is determined by both the initial topology of EC cords and the
persistence of collagen. Histological analyses suggest that the collagen ‘cores’ within
implanted cords showed no signs of degradation even 28 days PI. These findings suggest
that the collagen cores, by providing persistent adhesive cues to the implanted cells,
allow them to better maintain their original conformation and form capillaries in situ.
Attempts at controlling vessel diameter by implanting EC cords with varying
diameters did not result in vessels that varied in size. Instead, numerous capillaries
adjacent to the collagen core were evident in cords of all sizes. These data suggest that
vessel diameter cannot be controlled via the implantation of larger cords. Indeed, large
vessels formed during development grow over a period of time rather than forming
spontaneously via vasculo- or angiogenesis (Adams & Alitalo, 2007). Additionally,
current approaches to engineer large vessels rely on complex methods that rely on the
generation of a physiologically accurate vessel in vitro (Matsumura, Hibino, Ikada,
Kurosawa, & Shin'oka, 2003). Thus, it is likely that future integration of larger vessels
into constructs with patterned EC cords will require a hybrid approach that combines two
distinct strategies for generating both larger caliber vessels and small capillaries.
Histological analyses revealed that implantation of EC cords fabricated using 150
µm wide microchannels results in the formation of several capillaries in each cord. Given
these results, one might hypothesize that an excess of implanted cells is driving the
formation of these multiple capillaries and that formation of single capillaries might be
possible by utilizing smaller microchannels (e.g. 10 µm) for generating cords. While such
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an approach would yield much greater control of the fidelity of the final vascular
architecture, it is also possible that the smaller number of cells per cord would result in a
less robust response upon implantation. Ultimately, studies such as these will be
necessary to better understand the extent of control that is possible over capillary network
geometry.
4.1.9 Remaining challenges for vascularization of engineered tissues via
implantation of endothelial cell cords
Perhaps the biggest challenge in tissue engineering today is the generation of properly
vascularized solid tissues (Vacanti, 2012). In the study presented here, we have
demonstrated the ability to generate a functional, patterned capillary network within
engineered hepatic tissues. While capillaries generated within the hepatic constructs
significantly increased albumin promoter activity over hepatocyte-only controls, the
overall levels of albumin produced were below physiologically relevant level. One of the
next steps in developing clinically viable engineered therapies is the scale up of the
vascularization technique to generate tissues that can replace or augment tissue function
in the host. Indeed, as many as 2x109 isolated hepatocytes are currently used in human
transplantation trials (Baccarani et al., 2005). In the hepatic constructs described here,
which contained at most one hundred thousand hepatocytes, the amount of albumin
secreted into the blood stream was very low. Next, we plan to generate constructs with an
increased number of hepatocytes and potential to augment liver function. A challenge
associated with this goal is that of successfully integrating patterned EC cords within a
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larger hepatic construct. We anticipate overcoming this goal by generating multilayered
tissue constructs.
Another challenge in the further development of our vascularization strategy is
that of implantation into non-immunosuppressed hosts. Most likely, an ‘all-rat’ model
could be used to demonstrate effectiveness in wildtype animals. Specifically, EC cords
could be generated using isolated rat endothelial and smooth muscle cells. While the
angiogenic potential of various endothelial cell lines may be different, we do not foresee
any additional complications in demonstrating feasibility in non-immunosuppressed
hosts. Ideally, cell-free approaches will ultimately ameliorate the need for cells and
overcome this challenge altogether.
Lastly, long-term studies must be performed to better understand the stability of
the vessels over time. Jain and colleagues have demonstrated the persistence of an
engineered vasculature up to one year in vivo (Koike et al., 2004). Here, the current end
point of 28 days does not allow for extensive remodeling and long-term function of the
vasculature. While capillaries formed within cords appear to recruit pericytes and are
non-leaky after 7 days, their prolonged function in an engineered tissue remains to be
tested. A potential complication in these types of studies may be the effectiveness of the
ECM material to provide proper structural support to the vessels. It is possible that
degradation of the surrounding fibrin matrix might compromise the integrity of the entire
tissue construct. Synthetic materials with controlled mechanical properties and
degradation rates may prove helpful in addressing these issues.
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4.2 Discussion of studies on proliferative regulation in IPAH SMCs
4.2.1 Generation of an in vitro arterial wall model
The mature arterial wall consists of an inner layer of endothelial cells surrounded by a
contractile smooth muscle layer, and abnormal cell behavior within the media contribute
to the pathogenesis of many vascular diseases including atherosclerosis and hypertension
(Chin & Rubin, 2008; Lusis, 2000). Most studies of diseased smooth muscle cells,
however, are limited to simple tissue culture models that utilize SMCs alone or animal
models that severely limit the scope of possible manipulations. Previous work has shown
that treatment of smooth muscle cells in culture with ascorbic acid stimulates the
expression of smooth muscle-specific markers and increases the synthesis of collagen
(Arakawa et al., 2003; Barone et al., 1985; Qiao et al., 2009). Based on these findings, we
sought to generate an in vitro arterial wall model by culturing a monolayer of endothelial
cells atop smooth muscle cells embedded within a collagen matrix. While an EC-SMC
bilayer is itself not novel, few studies have reported the use this model in studies of
vascular disuse (Fillinger et al., 1997; Niwa et al., 2007).
Our findings indicated that endothelial cells, even when seeded at high densities,
did not attach and spread to form monolayers. Instead, our results suggest they do not
spread extensively and intergrade into the confluent layer of smooth muscle cells,
perhaps even attaching directly to the underlying glass substrate. Although we did not
perform imaging of the EC-SMC layers in cross section, it is likely that the amount of
ECM deposited by SMCs at the time of EC seeding was not high enough to prevent the
ECs from making contact with the glass substrate. Indeed, previous studies describing the
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development of arterial wall models relied on an exogenous collagen gel to fully
encapsulate the SMC layer prior to seeding ECs (Niwa et al., 2007; Ziegler et al., 1995).
In addition to the quantity of ECM deposited by SMCs, its identity must also be
considered. Endothelial cells have been shown to form monolayers when cultured on type
I collagen gels and this method is a routinely used model of angiogenic sprouting
(Bayless, Kwak, & Su, 2009; W. Koh, Stratman, Sacharidou, & Davis, 2008). Culture of
endothelial cells atop other matrices such as reconstituted basement membrane
(Matrigel), however, elicits networking behavior (Goodwin, 2007). It is plausible that the
more complex matrix secreted by SMCs treated with ascorbic acid contains components
that prevent the ECs from forming a fully confluent monolayer. It could be hypothesized
that one such component of the secreted matrix might be elastin, whose deposition has
also been shown to be increased upon stimulation with ascorbic acid (Barone et al.,
1985). Lastly, the source of the cells used in the generation of an arterial wall model must
be considered. While in our studies we have used bPAECs, the studies previously
mentioned in this section have mostly utilized HUVECs. Given that endothelial cells
from different sources possess various levels of angiogenic potential, the studies
described here should be tested using HUVECs (Auxenfans et al., 2011). The initial goal
of our studies was to develop an arterial wall model in which ECs and SMCs derived
from the lungs of patients with IPAH could be used. Because of the potential for different
responses due to cell source, such a system will have to be thoroughly tested for
robustness with endothelial cells from a variety of sources including human adult lungs.

141

Given the inability to recreate the published arterial wall models described here,
we decided to pursue an understanding of IPAH SMC pathology in more traditional
tissue culture models. If future attempts at using these cells to generate EC-SMC bilayers
is to be made, several considerations must be taken. First, a more thorough
characterization of confluent SMCs treated with ascorbic acid is necessary.
Immunofluorescent staining of cultures for collagen I and elastin should be performed to
better understand the composition of the secreted matrix, while sectioning and
histological should be used to observe the physical properties of the cell layers in cross
section. Second, the use of exogenous collagen matrix should be considered. While
allowing the cells to deposit their own ECM is preferable due to physiological relevance,
production of type I collagen within the medial compartment has been observed in vivo
(Rattazzi, Bertacco, Puato, Faggin, & Pauletto, 2012; Wolinsky, 1970). Thus, inclusion
of exogenous collagen might not have a negative impact on the physiological relevance
of an arterial wall model and should not be ruled out. Lastly, parameters for seeding cells
within the system such as numbers of cells used and the length of ascorbic acid treatment
should be further explored. Namely, the number of endothelial cells used and length of
culture should be extended. By utilizing DiI-AcLDL and seeding larger numbers of ECs
seeded atop SMCs, more favorable results are likely to be achieved. In summary, with the
incorporation of these changes we predict that an arterial wall model could be used to
better study IPAH PASMC biology in an in vitro setting.
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4.2.2 Mechanisms underlying abnormal proliferation in IPAH smooth muscle cells
Results described in Chapter 3 indicate that PASMCs isolated from lungs of patients with
IPAH exhibit increased proliferation when cultured in vitro. While hyperproliferation in
PAH SMCs has previously been documented (Chin & Rubin, 2008), our insights into the
underlying abnormal regulation of proliferative control in IPAH SMCs provide a novel
insight into the pathobiology of the disease.
Here, we show that IPAH SMCs exhibit increased RhoA activity and larger focal
adhesions. These findings are likely explained by previous studies, which have shown
that increases in Rho-dependent contractility lead to the aggregation of integrins into
focal adhesions (Chrzanowska-Wodnicka & Burridge, 1996). While not statistically
significant, data presented here also suggest that myosin light chain phosphorylation
might be increased in the IPAH cells. More in depth studies of MLC phosphorylation in
conjunction with immunostaining for integrins would help clarify whether similar
mechanisms underlie the hyperproliferative behavior in IPAH SMCs.
Next, our investigation into focal adhesion signaling showed that higher levels of
FAK are phosphorylated in IPAH SMCs as compared with control cells. This finding is
consistent with studies that demonstrate that overexpression of FAK leads to G1/S cell
cycle progression (Gilmore & Romer, 1996; Zhao, Reiske, & Guan, 1998). Our findings
also suggest that increased FAK activity in the IPAH PASMC prevent their ability to
normally regulate adhesion-mediated proliferative control. FAK, a key effector in focal
adhesion signaling, is involved in their formation, which allows for cell spreading and the
establishment of cytoskeletal tension (Burridge & Chrzanowska-Wodnicka, 1996; C.
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Chen et al., 1997; Chrzanowska-Wodnicka & Burridge, 1996; Guan & Shalloway, 1992;
Kornberg et al., 1992; Lewis & Schwartz, 1995; Pirone et al., 2006; Richardson et al.,
1997; Roovers & Assoian, 2003). Notably, FAK has been implicated as a key player in
adhesion-mediated proliferative control via the RhoA signaling pathway, which is
downstream of cell adhesion to the extracellular matrix (Chrzanowska-Wodnicka &
Burridge, 1996; Pirone et al., 2006). Additionally, FAK has been shown to regulate the
activity of RhoA, which is required for sustained ERK signaling and cell cycle
progression (C. Chen et al., 1997; Danen et al., 2000; Raines, 2000; Ren & Schwartz,
2000; Welsh et al., 2001). Given the central role of FAK as a signaling hub between the
extracellular environment and intracellular signaling, it is not surprising that it may play a
role in the abnormal proliferative regulation observed in SMCs in a disease that involves
significant mechanical and biochemical changes to the extracellular environment. To
better understand the role of adhesion signaling in IPAH, we suggest that subsequent
studies focus on investigating whether proliferation of IPAH PASMCs can be controlled
via changes to their adhesive microenvironment. Specifically, cells could be plated on
compliant gels or even embedded in a three dimensional arterial wall model such as that
described above. Measurements of FAK and Rho activity in these contexts of altered
adhesion might shed further light on the causative agents in the hyperproliferative
phenotype previously observed. In the more immediate future, our experimental plans
focus on confirming that FAK inhibition via genetic manipulations leads to a restoration
of normal proliferative behavior in the IPAH SMCs.
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4.2.2 Assessing the phenotype of IPAH smooth muscle cells
One of the biggest challenges in studies of rare diseases such as IPAH is the ability to
acquire reliable source material. Due to the relatively low prevalence of PAH,
approximately 1300 cases per million, the number of patients with the potential to donate
tissue or other source material is extremely limited (McDonnell, Toye, & Hutchins,
1983). The resection of lung tissue is a highly invasive procedure that cannot be justified
for the purpose of acquiring research material. Thus, the majority of human lung tissue
used in the study of IPAH is obtained from patients who have undergone lung
transplantation. Because transplantation is a treatment option of last resort, however, cells
in these lungs have often been subjected to a variety of treatments for several years.
Ultimately, human cells isolated and used in any in vitro study of IPAH mechanisms are
likely to exhibit considerable levels of heterogeneity. We acquired cells from IPAH
patients via laboratories at the University of Pennsylvania participating in the Pulmonary
Hypertension Breakthrough Initiative. Using cells from this single source insured a
consistent level of quality control – all SMCs were isolated, propagated and frozen using
identical protocols. Factors such as age, sex and clinical history, however, were not
controlled due to the scope of the study. Indeed, the data presented in Chapter 3
represents findings from at most 3 diseased and 3 control samples. In future studies,
larger cohorts will be necessary to ensure no bias is introduced due to donor variability.
Similar challenges are faced when selecting control cells for use in these studies.
While commercially available sources of human pulmonary artery smooth muscle cells
ensure a high level of consistency and quality control, their methods of isolation
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(including source within the lungs), propagation, maintenance and cryopreservation do
not match that of the independently acquired PAH cells. In order to mitigate some of this
bias here, we have used control cells that were obtained through both commercial sources
and isolated at the same laboratories as the IPAH cells. Our findings, however, should be
independently validated as additional donor cells become available.
4.2.3 Clinical translation of findings
The insights into abnormal proliferative regulation in IPAH SMCs presented in Chapter 3
require additional validation to have direct applications in the clinic. First and foremost,
our findings must be validated in a larger study. Such a study should include several
additional lines of donor control and IPAH cells and should include additional
manipulations not performed here. While we have shown initial evidence that inhibition
of FAK in an unspread context results in the return of proliferation to normal levels in
IPAH SMCs, additional studies utilizing genetic manipulations in larger donor cell
populations might help to solidify the link between FAK and proliferation in IPAH.
Specifically, overexpression of dominant negative FAK or Rho in additional donor cells
might be used to validate our proposed mechanism of proliferative misregulation.
Next, potential drug targets must be identified in animal models of pulmonary
hypertension such as hypoxia or monocrotaline treatment in rats (Stenmark, Meyrick,
Galie, Mooi, & McMurtry, 2009). While our data suggest that FAK inhibition has the
potential to restore proliferation in IPAH SMCs to normal levels, its inhibition must be
tested in vivo. Recently, the inhibition of smooth muscle myosin and RhoA, both
downstream effectors of focal adhesion signaling, have shown promise in animal models
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(Ho et al., 2012; E. Z. Xu et al., 2010). While these treatments offer to reduce pulmonary
arterial pressure via vasodilatory effects, our work suggests that further studies into their
potential antiproliferative effects might also be warranted. Given that our data have
demonstrated a mechanosensitive component to the abnormal proliferation in IPAH
SMCs, an eventual cure might involve inhibition of molecules such as FAK or integrins,
which act as signaling hubs between the extracellular environment and intracellular
pathways.

4.3 Future directions
4.3.1 Applications of vascularization via patterned EC cords
Vascularization of engineered tissues is perhaps the biggest obstacle that we face toward
the development of clinically viable tissue engineered therapies (Jain et al., 2005;
Rouwkema et al., 2008; Vacanti, 2012). Here, we have demonstrated the ability of our
vascularization strategy to be incorporated into engineered hepatic microtissues. While
much work still remains to be done in order to scale this approach up to larger tissues, we
believe that this is largely an engineering problem and expect no significant biological
barriers. Ultimately, we propose that large scale versions of our technique might be
employed to rapidly and effectively vascularize complex tissues such as liver, kidney and
pancreas. As a first step in achieving clinical efficacy, such engineered tissues are likely
to only augment failing tissue function rather than provide a complete organ replacement.
Challenges including cell source, immunogenicity, and host-graft integration must be
overcome on the road to true organ replacement therapy.
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Additionally, we envision vascularization via implantation of patterned EC cords
as having the ability to vascularize wounds or areas of ischemic tissues. Specifically, gels
containing cords could be used as a dressing in applications such as diabetic ulcers and
infarcted cardiac tissue. A particular challenge in the area of wound treatments will the
that of source material. In situations requiring the revascularization of ischemic tissues,
the length of time until initiating the treatment is critical for ensuring the best clinical
outcomes. To overcome these challenges, future research should focus on identifying
sources of autologous cells that are amenable to rapid isolation, expansion, and use in
implantable tissue constructs/wound healing materials.
In a research setting, we propose that vascularization via EC cords might be used
as a model to study the effects of vascular architecture on the efficiency of nutrient
delivery and waste removal via the circulation. Currently, much is known about the
mechanisms underlying vascular patterning (LaRue et al., 2003). Studies have also shown
that an increased level of vascular patterning in engineered tissue improves the
engraftment and vascularization rates of those tissues (X. Chen et al., 2009; Koffler et al.,
2011). However, it is not currently well understood what is the optimal topology of
vascular architecture in tissue engineered contexts. This area has been poorly studied
largely due to the lack of an experimental technique that allows for the patterning of
vessel networks in vivo. We propose that the method of patterning capillaries described
here could be used to study how different vascular architectures affect the delivery of
oxygen and nutrients to surrounding tissues in vivo. It would be of particular interest to
embed cells containing reporters of metabolic activity within the parenchyma of
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engineered tissues containing varying topologies of EC cords. Combined with in vivo
imaging, these types of experiments could be used to test a variety of models of optimal
tissue architecture.
Lastly, we envision the development of diagnostic tools that utilize tissue
engineered constructs at their core. While these types of technologies will surely require
years of research to reach the clinic, vascularization techniques such as the one described
here might lie at the core of these approaches. Real-time monitoring of various
circulating biomarkers is an area of particular interest (Ardill & O'Dorisio, 2010; De
Mattos-Arruda, Olmos, & Tabernero, 2011; Masson, Latini, & Anand, 2010). Rather than
externally tapping into existing vessels, we envision implantable devices or sensor-laden
tissue constructs that become vascularized independently. In such an application,
predicting areas that will become vascularized will be of key importance. Thus, strategies
for patterning vessels such as the one described here could be used in the development of
these technologies.
4.3.2 Future understanding of proliferative regulation in IPAH
Management of PAH has improved significantly over the last decade, and patients now
experience a higher quality of life (Agarwal & Gomberg-Maitland, 2011). New
treatments, however, continuously rely on the same categories of drugs to treat symptoms
of the disease with no clear signs of an emerging cure. We believe that mechanistic
studies such as the work presented in Chapter 3 are critical to further uncovering the
pathogenesis of IPAH. Here, our data suggest that abnormal SMC proliferation in IPAH
has a mechanical or adhesive component. Identifying the source of these extracellular
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cues should will be the focus of our future studies in this area. Elucidating the causative
factors that create a permissive microenvironment for abnormal proliferative regulation in
PASMCs could lead to the discovery of an underlying cause of IPAH and pave the way
for the development of future therapies. Lastly, it should be noted that efforts that
implicate other signaling factors such as PDGF in the etiology of IPAH are currently
underway (Ikeda et al., 2010). Future investigations into whether these pathways overlap
with the proliferative misregulation we report here will be key to identifying drug targets
and gaining a broader understanding of the pathobiology of IPAH.
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